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Two species belonging to different families were investigated, Eucomis montana from 
the Hyacinthaceae and Agapanthus inapertus from the Agapanthaceae. 
To date no previous chemical investigation on Eucomis montana has been reported. 
Eucomis species are routinely harvested, processed and sold for the treatment of 
various ailments ranging from toothache, gastro-intestinal ailments, pain-producing 
ailments and venereal and urinary diseases. Members of the genus have shown to 
contain steroidal compounds and homoisoflavonoids. In this work one 
nortriterpenoid, a eucosterol type derivative and eleven homoisoflavonoids belonging 
to four classes, the 3-benzyl-4-chromanone, the 3-benzyl-3-hydroxy-4-chromanone, 
the 3-benzylidenyl-4-chromanone and the scillascillin type were found in the bulbs of 
Eucomis montana. 
Agapanthus species are also used by a number of African tribes medicinally. The 
bulbs and rhizomes of this family have been reported to contain steroidal saponins 
and sapogenins. In this work the roots of Agapanthus inapertus have been 
investigated and a tignan precursor and a lignan have been found. 
Structures of the compounds isolated were determined usmg spectroscopic 
techniques. 
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CHAPTER 1: INTRODUCTION 
1.1. General 
The use of plants as a source of medicine dates back to antiquity. Plants were thought 
to have healing powers, perhaps as early as by Neanderthal man. The earliest 
documented uses are found in Babylon circa 1770 BC in the code of Hammurabi and 
in ancient Egypt circa 1550 BC. In fact, ancient Egyptians believed medicinal plants 
to be useful in the afterlife of their Pharaohs. i 
Plants play a fundamental role in many cultures, particularly for their medicinal 
purposes and a close tie between the study of plants and medicine exists. i Around the 
nineteenth century, emphasis was placed on the extraction of pure substances from 
plant material. Of these substances, few proved satisfactory as therapeutic agents, 
others being more toxic. The search for less toxic medicines based on natural sources 
resulted in the introduction of synthetic substances as drugs. These are often based on 
pharmacologically active compounds isolated from plants.2 
Despite advances in modem medicine, traditional medicine still remains popular 
among indigenous people throughout the world. For instance, in Africa, many plants 
are used for medicinal purposes. Although there have been a number of 
documentations on traditional African medicine, this form of therapy is often 
overshadowed by modem medicine. As there is a gradual decline in the number of 
traditional healers, valuable information on medicinal plants is being lost. To 
counteract this problem, certain African countries have introduced measures to 
preserve the traditional healer network. The list of biologically active principles 
isolated from African medicinal plants is growing all the time.3 Already African 
plants such as the calabar bean (Physostigma venenosum) and Devil's claw 
(Harpagophy/um procumbens) have made it onto the pharmaceutical market. 
Papaver somniferum, the opium poppy, is one of the earliest reported plants to be 
used medicinally. Its use was first documented in the writings of Theophrastus in the 
third century BC and it became popular among the Arabian, Chinese, Portuguese and 
English physicians.4 Today the main producer of medicinal opium is India. Several 
1 
alkaloids have been extracted from opium with morphine being the major component. 
Morphine is known to be one of the best analgesics for severe pain relief. Codeine, 
the methoxy derivative of morphine, is a minor opium constituent. It has valuable 
antitussive effects, helping in the prevention and relief of coughs. Papaverine, another 
alkaloid isolated from the seed, possesses spasmolytic and vasodilatory activity. 
Several analgesic drugs using morphine as a model have been synthesized. Of these 
heroin, originally synthesized as a cough suppressant, is most addictive and this has 
led to the creation of a drug problem.5 
morphine RJ=R2=H 
codeine RJ=H; R2=CH3 
heroin RJ=R2= COCH3 
Figure 1.1: Structures of alkaloids from Papaver somniferum 
Around the 1600' s, the bark from the tree Cinchona officinalis indigenous to South 
America drew much interest. It was used as an infusion to treat fevers by the 
European consumers and was referred to as the fever bark. Jesuit priests became the 
main importers and distributors of cinchona and the name "Jesuit bark" was later 
adopted.4 The bark's active ingredient is the alkaloid quinine, which is used in the 
treatment of malaria caused by the parasite Plasmodium Jalciparum. Other important 
alkaloids found in the cinchona bark are quinidine, cinchonidine and cinchonine.5 
Figure 1.2: Structure of quinine 
2 
Another plant, Artemisia annua, known as "ginghao" in Chinese traditional medicine, 
is also used in the treatment of fevers and malaria. The antimalarial drug artemisinin 
isolated from this plant is effective against drug-resistant strains of P. falciparum. 5 
The coca plant has proven to be useful from ancient times. In Andes cultures the coca 
leaves are mixed with lime to activate the pharmacologically active part of coca, 
cocaine, and then chewed. Cocaine acts as an antifatigue agent and this allows 
labourers to ignore hunger, fatigue and cold, enhancing physical activity and 
endurance. Cocaine was found to paralyse nerve endings, and was used as a local 
anaesthetic in several surgical and dental procedures. Erythroxylum coca and E. 
truxillense are the most prominent sources of cocaine. Procaine, the synthetic drug 
based on the cocaine structure is employed to provide a safer, less toxic local 
anaesthetic.5 
The leaves of the jaborandi tree, Pilocarpus jaborandi, native to Brazil, are popular as 
a folk medicine. In the form of tea, they are used as a diuretic and may be applied to 
the scalp to prevent baldness. It is also used to treat diabetes, asthma and a number of 
diseases including pleurisy and rheumatism. The leaves produce a gland rich in 
alkaloids such as pilocarpine. Pilocarpine is used to treat the blinding disease 
glaucoma.6 Currently pilocarpine and its analogues are being investigated for the 
treatment of Alzheimer's disease.5 
Figure 1.3: Structure of pilocarpine 
The use of Rauwolfia plant extracts may be traced back to ancient Hindu Ayurvedic 
writings. They were used to prepare primitive remedies for diseases such as 
hypertension, insomnia and insanity.4 Rauwolfia species found in India, Africa and 
the Caribbean produce large amounts of the therapeutically active compounds, 
reserpine and deserpidine. These alkaloids are used as antihypertensives and mild 
tranquilizers.5 
3 
Figure 1.4: Structure of reserpine 
The Madagascan periwinkle plant, Vinca rasea, has been shown to possess beneficial 
medicinal properties. As a folk medicine it is used as a tea for diabetes. Investigation 
into the possible hypoglycaemic activity of the plant indicated its anticancer potential. 
This has led to the isolation of some one hundred and fifty alkaloids, many of which 
have demonstrated useful antitumor activity, including vinblastine, vinrosidine, 
vinleurosine and vincristine. Of these, vincristine and vinblastine are considered to be 
extremely valuable drugs in cancer chemotherapy. Vinblastine is used mainly in the 
treatment of Hodgkin's disease while vincristine is more neurotoxic.5 
Another plant known for its anticancer properties is the Pacific Yew, Taxus brevifalia. 
The bark of this plant has produced the anticancer drug Taxol (paclitaxel). Taxol is 
used clinically to treat ovarian, breast and lung cancers and cancers of the brain and 
neck. The problem experienced with Taxol, however, is that the amount of active 
ingredient produced from the plant is enough to treat only one patient and it takes 
several years to grow the plant. Currently a semi-synthetic form of Taxol is being 
produced.5 
Figure 1.5: Structure of Taxol 
4 
These are a few, yet classic, examples of plant-derived medicinals. The Plant 
Kingdom has provided us with a virtually untapped wealth of healing gifts and will 
continue to provide a rich, virtually inexhaustible supply of new potential drugs. 
Problems with drug resistant micro-organisms, side effects of modem drugs and 
emerging diseases where no drugs are available encourages the investigation of plants 
as a vital source of medicine. It is therefore imperative that modem-day researchers 
fully appreciate the vast medicinal knowledge of indigenous people in their quest for 
drug discovery. 
5 
1.2. The Hyacinthaceae and the Agapanthaceae 
1.2.1. Introduction to the Hyacinthaceae 
The Hyacinthaceae is the family of hyacinths and related plants. Formerly part of the 
Liliaceae sensu lata, the family has two centres of diversity, one being southern 
Africa, while the other, stretches from the Mediterranean to South-West Asia.
7 
It 
comprises sixty-seven genera and nine hundred species worldwide, with three 
hundred and sixty-eight species and twenty-seven genera locally represented. 8,9 
Although there has been great difficulty in the classification of the family, five 
subfamilies have now been identified. Of these, the Urgineoideae, Ornithogaloideae 
and Hyacinthoideae are found in southern Africa.7,8 
Members of the Hyacinthaceae are bulbous perennial herbs. They are widespread and 
well adapted to the moist, arid climate in southern Africa.7 
The compounds isolated from the Hyacinthaceae are generally classified into four 
groups: homoisoflavonoids, steroidal type compounds, bufadienolides and 
miscellaneous type compounds. 10 The occurrence and biosynthesis of 
homoisoflavonoids are described in detail in chapter 2. Steroidal type compounds 
include spirocyclic nortriterpenoids and cholestane glycosides/steroidal saponins and 
their derivatives. The characteristic feature of cholestane glycosides is a basic 
cholestane triterpenoid skeleton.5,10 Classification and biosynthesis of spirocyclic 
nortriterpenoids is described in chapter 2. Bufadienolides are one of a group of two 
types of cardiac glycosides. Cardiac glycosides are characterized by a steroidal 
aglycone attached to a sugar moiety. The cardenolides have a ~-substituted, 
unsaturated, five membered lactone ring at C-17 and the bufadienolides have a ~­
substituted, doubly unsaturated, six membered lactone ring at the same position.5,10 
Miscellaneous type compounds include compounds such as chromones, stilbenes, 














Rl = ~-D-glc 











Figure 1.6: Examples of some types of compounds isolated from Hyacinthaceae, (i) 
homoisoflavonoid, (ii) cholestane glycoside, (iii) bufadienolide, (iv) acid, (v) phenolic compound, 
(vi) spirocyclic nortriterpenoid and (vii) cardenolide 
1.2.2. Introduction to the Agapanthaceae 
The genus Agapanthus was initially included in the Aliaceae, and then moved to the 
Amaryllidaceae_ It is now placed in its own family, the Agapanthaceae. These 
previous inclusions were based on whether the umbellate inflorescence is considered 
to be of greater taxonomic importance than its superior ovary.Il,12,J3 
Species of the family Agapanthaceae have been found to contain steroidal 
saponins. 11,12 Steroidal saponins are C27 sterols in which the cholesterol side chain has 
7 
been modified to produce a spiroketal and usually a sugar residue is attached at C-3. 
Hydrolysis of the sugar unit at C-3 produces compounds called sapogenins.5 
RO 
0--./ 
i. R=sugar residue 
ii.R=H 
Figure 1.7: Structure of a (i) saponin and (ii) sapogenin 
The Agapanthaceae is a monotypic family i.e. it consists of only one genus, 
Agapanthus. This family is indigenous to southern Africa. Agapanthaceae comprises 
ten variable species widespread in all provinces of South Africa, except for the 
Northern Cape. It is also found in Lesotho and Swaziland. 13,14 They are found in areas 
where the rainfall is more than 500 mm per annum, from sea level to 2000 m.13 Its 
natural distribution extends from the Cape Peninsula in the south-west, along the 
southern and eastern coast of southern Africa, then inland and northwards into the 
mountainous regions of the Limpopo River. 13,14 
The name Agapanthus is derived from the Greek word agape, meaning love and 
anthos, meaning, flower. 13 These plants require sun or lightly shaded positions for 
optimum growth and flowering. Both deciduous and evergreen species occur.14 
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1.3. Species investigated 
1.3.1. Eucomis montana (Hyacinthaceae) 
Eucomis montana is one often species of the genus Eucomis L'Heritier. Members of 
this genus are mostly endemic to southern Africa and are found in the eastern and 
north-eastern regions, except Eueomis regia which occurs in the Western and South-
Western Cape. 14 
All species of Eueomis are deciduous geophytes and summer growing. They have 
large bulbs that produce a rosette of smooth, usually shiny leaves. The inflorescence 
is a spike of scented white, pale green or yellow flowers, bearing a tuft of leaf-like 
bracts at its tip that resemble a pineapple. The name pineapple-flower is often 
employed. 14,15 
Figure 1.8: Photograph of Eucomis montana inflorescence 
by Neil Crouch 
Although actual uses of Eucomis montana have not been documented, indigenous 
people of southern Africa use other members of Eueomis in the treatment of various 
ailments. The Southern Sotho use E. hieolor as a colic remedy and E. regia as a 
remedy for venereal disease. Decoctions of the bulbs of E. punetata are used by the 
Xhosa as a treatment for rheumatism and given as an enema to children during 
teething while decoctions of the bulbs of E. undulata is a Pedi remedy for abdominal 
pain. The Zulu take decoctions of a Eueomis sp. (probably E. regia) for the treatment 
of respiratory conditions, especially cough, and as an enema for biliousness. 16 
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Previous investigations of the Eucomis genus have yielded homoisoflavonoids (1-111), 
spirocyc1ic nortriterpenes (IV), lanosterol oligosaccharides (V), acids (VI), dibenzo-
a-pyrones (VII) and chromanones (VIII). These are listed below. 
I) 3-benzyl-4-chromanone type homoisoflavonoids 
Rs 
Name Rl Rz R3 ~ Rs Ref 
1. 3,9-dihydroeucomin OH H OH H OCH3 17,18 
2. 7 -O-methyl-3,9-dihydro- OH H OCH3 H OCH3 18 
eucomin 
3. 3,9-dihydropunctatin OH H OH OCH3 OH 19 
4. 4'-O-methyl-3,9-dihydro- OH H OH OCH3 OCH3 19 
punctatin 
S.4'-demethyl-S-O-methyl-3, OCH3 H OH H OH 19 
9-dihydroeucomin 
6. 3,9-dihydroautumnalin OH OCH3 OH H OH 20 
II) 3-benzyl-3-hydroxy-4-chromanone type homoisoflavonoids 
Rs 
Name Rl Rz R3 ~ ~. Ref 
7. eucomol OH H OH H OCH3 21 
8. 7-0-methyleucomol OH H OCH3 H OCH3 18 
9.3,S,7-trihydroxy-3-(4'- OH H 
hydroxybenzyl}4~bromanone 
OH H OH 17 
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III) 3-benzylidenyl-4-chromanone type homoisoflavonoids 
Rs 
Name RJ R2 R3 Itt R5 Ref 
10. eucomin OH H OH H OCH3 21 
11. punctatin OH H OH OCH3 OH 19 
12.4'-O-methylpunctatin OH H OH OCH3 OCH3 19,20 
13.4'-demethyleucomin OH H OH H OH 19 
14. autumnalin OH OCH3 OH H OH 20 






Name R) R2 R3 ~ Rs Ref 
15. eucosterol OH CH3 =0 H H 22 
16. 16p-hydroxyeucosterol OH CH3 =0 OH H 22 








19. 16p-hydroxyeucosteroI3p- [0- a-L-rha-(1-+2)- CH3 =0 OH H 23 
0-[ O-a-L-rhamnopyranosyl- O-~-D-glc-(1-+ 2)-0-
(1-+ 2)-0- P-D-glucopyranosyl- a-L-arab-(1-+6)-~-D-
(1-+ 2)-0-a-L- glc] 
arabinopyranosyl-(I-+6)-P-D-
glucopyranoside] 
20. 15-deoxo-30- {O- a -L-rha-(1-+2)- CH20H H H H 23 
hydroxyeucosteroI3p-0-{ O-a- 0-[~-D-xyl -(1-+3)] 
L-rhamnopyranosyl-(1-+2)- 0- O-~-D-glc-( 1-+2)-0-
[P-D-xylopyranosyl-(I-+3)]-0- a-L-arab-(1-+6)-~-D-
p- D-glucopyranosyl-(I-+2)-0- glc} 
a-L-arabinopyranosyl-(1-+6)-P-
D-tzlucopyranoside} 
21. eucosteroI3p-0-{0-a-L- {O- a-L-rha-(1-+2)- CH3 =0 H H 23 
rhamnopyranosyl-(l-+ 2)-0-[P- 0-[~-D-xyl-(1-+3)] 




V) lanosterol oligosaccharides 
Name R) Ref 
22. scilla saponin A 0-a-L-rha-(1-+2)-0-[~-D-xyl-(1-+3)]-0- 23 







5a-chola-8 16-dien-23-oic acid 
24. eucomic acid 
VII) dibenzo-a-pyrones 
Name Rl 
25. autumnariol* R 








* These published structures are incorrect. They are actually xanthones and structures are being 
corrected in a PhD thesis currently being prepared by C. Koorbanally of the Natural Products 







Table 1.1: List of compoun s ISO ate rom varIOUS d . I d f E ucom,s species 
Eucomis species Compounds isolated 
E. hicolor 1,2,7,8,9,10,15,16,17,18,19,20,21,22 
E. comosa (8yn E. punctata) 3,4,5,11,12,13,15,24,27 
E. autumnalis (8yn E. undulata) 6, 12,14,15,23,25,26 
E. pole-evansii 15 
1.3.2. Agapanthus inapertus (Agapanthaceae) 
Agapanthus inapertus is also known as the Drakensburg Agapanthus, drooping 
Agapanthus, bloulelie and hlakahla. Agapanthus inapertus is an attractive, tuberous 
plant, which occurs naturally in open grassland and forest margins through 
Mpumalanga, Swaziland, northern Kwazulu-Natal, Gauteng and the Northern 
Province where it is found in the mountainous, rocky areas and commonly along the 
Drakensberg Escarpment. 
A striking feature of these plants is the beautiful dark blue to violet flowers held in 
dense stalks up to 1.5 m high. Individual flowers are tubular and pendulous hence the 
name "drooping agapanthus" is often used. There are five subspecies of Agapanthus 
inapertus, which are distinguished from each other on the basis of shape and size of 
the flowers?6 
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Figure 1.9: Photograph of Agapanthus inaperlus inflorescence 
by Dr Neil Crouch 
Members of Agapanthus have been reported to have medicinal uses. South African 
traditional healers use A. africanus plants in herbal remedies to treat pregnancy-
related ailments and to allow an easy childbirth. The leaves and roots are prepared as 
antenatal medicines in the form of decoctions or infusions. 16,27 Infusions of the root 
are used by the Zulu to help with chest pains and cough. The bulb of A. orientalis is 
used as a Zulu aphrodisiac. 16 




Figure 1.10: Compounds isolated from Agapanthus species 
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Name Rl Ref 
1. A2apantha2enin H 28 
2. Agapanthussaponin A 3-0-[ a-L-Rahmnopyranosyl-(l-+ 2)-[P-D- 29 
galactopyranosyl-(l-+ 3)1-13-D-glucopyranoside] 
3.7-dehydroagapanthagenin H 28 
4. Agapanthussaponin B 3-0-[ a-L-Rahmnopyranosyl-( 1-+ 2)-[P-D- 29 
galactopyranosyl-( 1-+ 3)1-13-D-glucopyranoside 1 
5.8(14)-dehydroagapanthagenin H 28 
6. 9(11 )-dehydroagapanthagenin H 30 
7. Agapanthussaponin C 3-0-[ a-L-Rahmnopyranosyl-(I-+ 2)-[P-D- 29 
galactopyranosyl-(l-+ 3)1-13-D-glucopyranoside 1 
8. Agapanthussaponin D 3-0-[ a-L-RahmnopyranosYl-{l-+ 2)-[P-D- 29 
galactopyranosyl-( 1-+3)]-13-D-glucopyranoside ] 
9. Furostano1saponin 3-0-[ a-L-Rahmnopyranosyl-(I-+ 2)-[P-D- 29 
galactopyranosyl-(l-+ 3)]-P-D-glucopyranoside ],26-
0-13-D-glucopyranoside,22-methylether 
10. Yucca2enin H 28 
Table 1.2: List of compounds isolated from Agapanthus species (see Figure 1.10) 
AlfflJJanthus species Compounds isolated 
A. africanus 1,3,5,6,10 
A. inapertus 2,4,7,8,9 
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CHAPTER 2: THE CLASSIFICATION AND 
BIOSYNTHESIS OF TRITERPENOIDS AND 
HOMOISOFLA VONOIDS 
In this work a eucosterol type nortriterpenoid and eleven homoisoflavonoids were 
isolated from Eucomis montana. The biosynthesis of these types of compounds will 
be discussed in this chapter. 
2.1. Occurrence and Classification of Triterpenoids 
Terpenoids are a large, diverse group of natural products widely distributed 
throughout the Plant Kingdom. A small, yet important group such as lanosterol, is of 
animal origin. The basic building blocks of terpenoids are C-5 isoprene units. The 
classification of triterpenoids is based on the number of isoprene units incorporated in 
the carbon skeleton. 1 
Figure 2.1: Structure of the isoprene unit 
Compounds that have thirty carbons are referred to as "triterpenoids" and are derived 
from squalene, which was first isolated from shark liver oi1.2 Triterpenoids occur as 
esters, glycosides or in the free state.3 
Figure 2.2: Structure of squalene 
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Spirocyclic nortriterpenoids are a class of compounds with a basic lanosterol 
triterpenoid skeleton that have been isolated from members of the Hyacinthaceae. The 
two main types are the eucosterol and 16~-hydroxyeucosterol types.4 In addition, 
lanosterol oligosaccharides with aglycone skeletons have been reported to occur in 
Velthemia viridifolia and Eueomis hieolor and spiro cyclic nortriterpenoid glycosides 
from Scilla seilloides. 5,6,7 These contain skeletons closely related to eucosterol. The 
variation in these compounds is due to the differing degree of oxygenation of the 
aglycone and different combinations of sugars. 
Two numbering systems are found in the literature for sterols. Older literature makes 
use of IUPAC-IUB rules for sterol nomenclature of 1967, but the more recent 
literature makes use of IUPAC-IUB rules for sterol nomenclature of 1989. Both 





Figure 2.3: Numbering system for sterols according to IUPAC-IUB rules of (i) 1967, (il) 1989 
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2.1.1. Eucosterol type Triterpenoids 
Figure 2.4: Structure of eucosterol 
Eucosterol is found to be a secondary metabolite of several Eucomis species. The 
structure and absolute configuration of eucosterol was determined by chemical and 
spectroscopic data and provides the basis for the structural elucidation of related 
compounds.4 The unique structural feature of eucosterol-type compounds is the 
spiro fused a -furanoic ether linkage between C-17 and C-23. 
A summary of characteristic resonances found in the lH NMR and l3C NMR spectra 
for eucosterol-type compounds is given below.4 
The lH NMR spectra show a multiplet between 8H 3.40 and 8H 3.60 for the H-3 
proton and a pair of doublets at 8H 3.30-3.50 and 8H 4.00-4.20 for the methylene 
protons of the CH20H group (2H-29). The methine proton at C-23 resonates as a 
triplet between OH 4.64 and OH 4.80. 
Six methyl groups are usually present in the molecule. The 3H-18 and 3H-19 methyl 
group protons resonate as singlets between 8H 0.87 and 8H 1.05 and the singlet 
resonances at approximately 8H 1.05-1.30 and 8H 1.27-1.41 belong to the methyl 
protons of 3H-28 and 3H-30 respectively. The 3H-26 methyl group proton resonance 
occurs as a triplet at approximately 8H 1.04-1.12. 
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The l3C NMR spectrum usually shows two carbonyl resonances at about Oc 215.0 and 
Oc 211.0 belonging to C-15 and C-24 respectively. The molecular formula for 
eucosterol itself shows the presence of five oxygen atoms, however the l3 C NMR 
spectrum shows six oxygen bonded carbons and this indicates the presence of the 
ether linkage between C-17 and C-23 forming the heterocyclic ring E. This can be 
proven by the fact that on acetylation of eucosterol, acetylation occurs only at C-3~ 
and C-29 indicating only two free hydroxyl groups. 
The l3C NMR spectrum also shows the presence of two fully substituted alkene 
resonances at about Oc 133.0-135.2 and Oc 133.1-137.0. With the aid of HMBC 
correlations these resonances can be assigned to C-8 and C-9. This accounts for one 
of the eight double bond equivalents expected in eucosterol with two belonging to the 
keto groups and the remaining five to the pentacyclic ring structure. 
The stereochemistry of the molecule can be determined from the NOESY spectrum. 
NOESY correlations between H-20 and 3H-18, 3H-21, H-22~ and H-25 indicate that 
the stereochemistry of C-20 is R. Correlations between H-23 and H-22u and 3H-21 
indicate that H-23 is u. Correlations between H-5u and H-3 and 3H-28 shows that H-3 
and 3H-28 are u. No correlation between H-5 and H-19 is seen which confirms that 
H-19 is ~ as expected. The 3H-21 and 3H-18 resonances show correlations with each 
other, as a result of the C-17, C-20 bond being ~. 
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2.2. Biosynthesis of Triterpenoids 
It is believed that the acyclic hexa-ene all trans-squalene is the biological precursor in 
the biosynthesis of triterpenoids. 1 This molecule undergoes a series of cyclizations to 
give different types of compounds. The Biogenetic Isoprene Rule proposes that the 
type of triterpenoid produced is dependent on the confonnation that squalene epoxide 
adopts presumably at the enzyme surface prior to cyclization. I,8 It is recognised that 
all sterols in animals originate from lanosterol and the precursor to sterols in plants is 
cycloartenol. I 
HO 
Figure 2.5: The structure of cycloartenol 
HO 
Figure 2.6: The structure of lanosterol 
The biochemically active isoprene units involved in squalene fonnation are the 
diphosphate (pyrophosphate) esters, isopentenyl pyrophosphate (IPP) and 
dimethylallyl pyrophosphate (DMAPP).9 
Combination of DMAPP and IPP via the enzyme prenyl transferase generates geranyl 
pyrophosphate (GPP), a ten carbon compound. This reaction involves ionization of 
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DMAPP to the allylic carbocation. This cation is then added to the double bond of IPP 
in a head to tail fashion. Loss ofa stereospecific proton results in GPp9 (Scheme 2.1). 












Scheme 2.1: The formation of geranyJ prophosphate9 
opp 
Addition of another molecule of IPP to GPP generates the fifteen carbon compound 
famesyl pyrophosphate (FPp).9 This mechanism (Scheme 2.2) proceeds in a similar 
manner to GPP formation. 
I~ I~ Olpp -_. ~ j ", opp ~o - ~ 






loss of proton 
1 
electrophilic addition 
gives tertiary carbocation 
Scheme 2.2: The formation offarnesyJ pyrophosphate9 
Squalene is formed from two molecules of FPP joined by a tail to tail linkage 
(Scheme 2.3). A proton from C-I of one molecule of FPP is lost and replaced with a 
proton from NADPH. This involves attack of the 2,3-double bond of FPP onto the 
famesyl carbocation in a manner similar to chain extension using IPP. Loss of a 
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proton from the tertiary carbocation formed, results in a cyclopropane ring and 
formation of presqualene PP. 
The loss of a diphosphate from presqualene PP results in an unstable primary 
carbocation, which undergoes a Wagner-Meerwein migration to generate a more 
stable tertiary carbocation. This is followed by bond cleavage in the cyclopropane 
ring and generation of a favourable allylic carbocation. Addition of a hydride ion from 








giving tertiary carbo cation 
...... oPp 
loss of proton with formation of 
cyclopropane ring 
H'~*.c'QPP loss .of dip~osphate G;i~* ,H 
gives pnmary I. '\ 
~/l ..- c~on~/l ..-
presqualene PP 
cation quenched by 







1,3-alkyl cyclopropane ring 




bond cleavage produces alkene 
and favourable allylic cation 
*= carbons involved in squalene 
formation 
squalene 
Scheme 2.3: The formation ofsquaJene' 
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Squalene 2,3-epoxide is the intermediate through which cyclization of squalene 
occurs. This reaction is catalysed by a flavoprotein requiring O2 and NADPH as 
cofactors. Protonation of the epoxide group allows opening of the epoxide ring and 
generation of the preferred tertiary carbocation. Electrophilic addition to the double 
bond follows and this allows for the formation of a six-membered ring. The process of 
generating a new carbocation after each ring formation continues until a tertiary 
protosteryl carbocation is formed. The cation then undergoes a sequence of Wagner-
Meerwein rearrangements. Loss of a proton results in formation of a double bond and 
formation of lanosterol (Scheme 2.4).9 





110"' of proID' giv" ,lire" 
Lanosterol 
Scheme 2.4: Proposed biosynthesis of lanosterol' 
Lanosterol is thought to be the precursor of eucosterol type nortriterpenoids. The 
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2.3. Biological Activity of Triterpenoids 
There have been reports on the biological activity of triterpenoids which indicates 
their potential as drugs. 
The anticancer activity of some pentacyclic and tetracyclic triterpenoids was tested 
against human cancer cell lines and showed interesting results. ll Among the 
pentacyclic triterpenoids, epimaniladiol was found to be cytotoxic against HEC-l-A, 
CAMA-l, ME-180, u-87MG, CALAU-l and SK-OV-3. Maniladiol, the 16~-epimer, 
was cytotoxic against ME-180 and CAMA-l and sophoradiol, which lacks the 16-
hydroxy group, showed cytotoxicity against ME-180 only. Furthermore, 
glycyrrhetinic acid and l1-oxo-~-amyrin, both with free 3~-hydroxy groups, were 
active against SK-OV-3 and CAMA-l respectively. These results suggested that the 





ii iii. 16f3 - OH 
iv.16a -OH 
Figure 2.7: Structure of (i) glycyrrhetinic acid, (ii) sophoradiol, (iii) maniladiol and (iv) 
epimaniladiol 
The hexacyclic nortriterpene pfaffic acid, isolated from the roots of Pfaffia 
paniculata, exerts high inhibitory effects on the growth of cultured tumor cells, such 
as melanoma (B-16), Hela (S-3) and Lewis Lung carcinoma cells. 12 
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HO 
Figure 2.8: Structure of pfaffic acid 
A number of lanosterol oligosaccharides from Eueomis bie%r, Scilla peruviana, 
Chionodoxa gigantea and Chionodoxa /uciliae have been screened for antitumor-
promoter activity in vitro. They were found to have an inhibitory effect on the tumour 
promoter 12-0-tetradecanoylphorbol-13-acetate (TP A)-stimulated 32P incorporation 
into phospholipids of HeLa cells. It is worth noting that introduction of a 16P-
hydroxy group into the eucosterols markedly reduced their activity.6 
22P-Hydroxy-15-deoxoeucosterol, isolated from Ledebouria zebrina, was recently 
tested against Fusarium moliniforme for antifungal properties and showed fungal 
growth inhibition. No other work on the biological activity of eucosterol type 
triterpenoids has been conducted. 1o 
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2.4. Occurrence and Classification of Homoisoflavonoids 
Homoisoflavonoids are a group of natural products of which the first representatives 
eucomol and eucomin, from the plant species Eueomis bieolor were reported in 
1967. 13 Homoisoflavonoids are found predominantly in the H yacinthaceae family, 
particularly in the genera Scilla, Eueomis and Museari 13-22, but a few have been 
reported from others. For instance, intricatin and intricatinol are two 
homoisoflavonoids found in the Fabaceae family?3 
Homoisoflavonoids, also referred to as homoisoflavanones, are a group of naturally 
occurring oxygen heterocycles.24 They have a sixteen-carbon skeleton instead of the 
fifteen carbon skeleton characteristic of isoflavonoids?O,25,26 It is believed that 
homoisoflavonoids are biosynthesized by modification of the C6.C3.C6 chalcone-
flavonoid skeleton by insertion of an extra carbon atom. The term 
"homoisoflavonoid", however, is somewhat misleading, since the characteristic 2,3-
aryl migration step in the biosynthesis of isoflavonoids does not occur in that of 
homoisoflavonoids. The systematic name 3-benzyl-4-chromanone is often preferred.2o 
The numbering system for homoisoflavonoids is shown below. The A and C ring is 
numbered with counting numbers and the B-ring, with primed numbers. 
o 
Figure 2.9: Numbering system for bomoisoflavonoids 
The carbon skeleton of homoisoflavonoids has a chromane, chromone or chromanone 
moiety to which is attached, in most cases, a benzyl or benzylidenyl group at position 
3.
25 
Substitution patterns on the A and B rings distinguish homoisoflavonoids from 
each other. Structural features of homoisoflavonoids have allowed classification into 
three types: (1) the 3-benzyl-4-chromanone or dihydroeucomin type, (2) the 3-benzyl-
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3-hydroxy-4-chromanone or eucomol type and (3) the 3-benzylidenyl-4-chromanone 
. 2427 or eucomm type. . 
There are three techniques employed for the structural determination of 
homoisoflavonoids. These are nuclear magnetic resonance spectroscopy (NMR) , 
ultra-violet spectroscopy (UV) and mass spectrometry. 
2.4.1. The 3-benzyl-4-chromanone or dihydroeucomin type 
3-benzyl-4-chromanone 
Figure 2.10: The 3-benzyl-4-chromanone type homoisoflavonoids 
The IH NMR spectrum shows a characteristic coupling pattern due to the coupled 2H-
2, H-3 and 2H-9 proton system for this type of homoisoflavonoid. A pair of double 
doublets is observed for the two non-equivalent H-2 protons at OH 4.10-4.32 and 
another pair of double doublets is observed for the non-equivalent H-9 protons in the 
range OH 2.65-2.73 and OH 3.10-3.26. The H-3 resonance occurs as a multiplet at about 
OH 2.72-2.87. 
2.4.2. The 3-benzyl-3-hydroxy-4-chromanone or eucomol type 
o 
3-benzyl-3-hydroxy-4-chromanone 
Figure 2.11: The 3-benzyl-3-hydroxy-4-chromanone type homoisoflavonoids 
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In the I H NMR spectrum a pair of doublets is observed for the two H-2 protons in the 
range OH 4.20-4.36 and OH 4.12-4.17. A second pair of doublets is observed for the 
2H-9 protons at OH 3.10-3.20 and OH 2.65-2.75. The multiplet at OH 2.72-2.87 is ~sen~ 
and this indicates the presence of a hydroxy substituent at C_3.
28 
2.4.3. The 3-benzylidenyl-4-chromanone or eucomin type 
o 
(Z)-configuration (E)-configuration 
Figure 2.12: The 3-benzylidene-4-chromanone type homoisoflavonoids 
The typical feature for this type of compound is the 3,9-double bond which may be in 
either the (E) or (Z) configuration. In the IH NMR spectrum a pair of doublets is 
observed for the two H-2 protons at approximately OH 5.20-5.50. The H-9 resonance 
occurs as a singlet whose chemical shift depends on the configuration of the molecule. 
In the (E) configuration the H-9 proton is in the anisotropic region of the carbonyl 
group and causes it to resonate at about OH 7.60-7.70. In the (Z) configuration, the 
proton at C-9 is away from the anisotropic region of the carbonyl group and the 
resonance for this vinyl group proton occurs at approximately OH 5.50.28•29 
In the I3C NMR spectrum, certain shifts are characteristic for homoisoflavonoids. The 
chemical shifts of C-2 in 3-benzylidenyl-4-chromanones, 3-benzyl-4-chromanones 
and 3-benzyl-3-hydroxy-4-chromanones occur at oe 67.5, oe 69.3 and oe 73.0 
respectively and can be used to distinguish one type of homoisoflavonoid from the 
other. The C-4 carbonyl group resonance also differs in its chemical shifts for the 
three types of homoisoflavonoids. For 3-benzylidenyl-4-chromanones, C-4 occurs at 
oe 182.0 because the carbonyl group is conjugated. The C-4 shifts for 3-benzyl-4-
chromanones and 3-benzyl-3-hydroxy-4-chromanones are distinctly different from the 
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3-benzylidenyl-4-chromanone type and appear at about oe 197.0 and oe 195.0 
respectively.24 The C-3 resonance occurs as an aliphatic methine resonance for the 3-
benzyl-4-chromanone type homoisoflavonoid and as an oxygenated, aliphatic 
quaternary resonance for the 3-benzyl-3-hydroxy-4-chromanone type. For the 3-
benzylidenyl-4-chromanone type homoisoflavonoids, the C-3 resonance occurs as a 
quaternary resonance in the double bond region. 
Other features of the lH NMR spectrum may assist in determining the substitution 
pattern on the homoisoflavonoid. The signals at approximately OH 6.50-7.20 usually 
indicate substitution on the B-ring. This is either an ABX or an AA'BB' system. The 
substituents present are attached at C-4' (AA'BB' system) or C-3' and C-4' (ABX 
system). The substitution pattern on the A-ring is indicated by resonances in the 
region OH 5.80-6.30. There are usually only one or two proton resonances in this 
region, which are normally due to H-6 and/or H-8. The position of the proton is 
normally assigned through the NOESY spectrum, which shows NOESY correlations 
with the substituents at C-5 and C-7. 
UV spectra are also importarJt in the determination of the substitution pattern on the A 
ring of homoisoflavonoids. The original UV spectrum of homoisoflavonoids gave an 
absorption maximum at 285-367 nm.28 Addition ofNaOAc and AICl) solutions causes 
the maximum to shift in some instances.28,30 These shifts are referred to as 
bathochromic shifts. A bathochromic shift observed with NaOAc indicates the 
presence of a hydroxy group at the C-7 position while a bathochromic shift with AICl) 
implies a hydroxy group at the C-5 position.28,31,32 
The mass spectrum is another diagnostic tool used in the determination of the 
structure of compounds. There are certain peaks that occur for homoisoflavonoids due 
to characteristic fragmentation patterns. In eucomol, cleavage of the C-3, C-9 bond in 
what is known as an A-4 type cleavage leads to fragments at mlz 195 and mlz 121 as 
shown in Scheme 2.6.28 The intense peak at mlz 121 is due to the methoxytropylium 
ion, which is the base peak of the spectrum. In eucomol, the chromanone fragment ion 
at mlz 195 may eliminate water, CO or undergo a retro-Diels-Alder (RDA) cleavage 
to give a fragment ion at mlz 152 or, due to a hydrogen shift, at mlz 153. The major 
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pathway is usually the RDA cleavage and hydrogen-shift. The minor pathway is 
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Scheme 2.6: Mass spectral fragmentation pattern for homoisoflavanones18 
Apart from these three basic structural types, several unusual homoisoflavonoids 
characterized by an additional fourth ring have been found. 24,26,27 Scillascillin-type 
compounds possess a 3-spiro-cyclobutenyl ring whereas brazilin homoisoflavonoids 
and haematoxylin homoisoflavonoids contain a cyclopentenyl ring. In scillascillin the 







Figure 2.13: Structure of scillascillin, brazilin and haematoxylin type homoisoflavonoids 
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2.5. Biosynthesis of Homoisoflavonoids 
Phenolic compounds can be biosynthesized by two routes: the shikimate pathway or 
the polyketide pathway. Often compounds, such as flavonoids and 
homoisoflavonoids, are of mixed biosynthetic origin. In homoisoflavonoids the A-
ring is polyketide derived and the B-ring is shikimate derived (Figure 2.14). 
Polyketide derived phenols produce a l ,3,5-oxygenation substitution pattern but it is 
common for one or more of these groups to disappear during the biosynthesis. 
Phenols from the shikimate pathway are always oxidised in the para-position but 













o shikimate derived 
Figure 2.14: The origin of the A and B rings of homoisoflavonoids 
The first step in the biosynthetic route leading to homoisoflavonoids involves 
chalcone formation as cha1cones are the precursors to homoisoflavonoids?O,26,28 
Formation of the chalcone precursor involves conversion of phenylalanine to 
cinnamic acid, which is catalysed by the enzyme phenylalanine ammonia lyase 
(PAL). PAL catalyses the anti-elimination of ammonia and the pro-3S-proton from L-






PAL=phenylalanine ammonia lyase 
~COOH 
V 
Figure 2.1S: Conversion of L-phenylalanine to trans-(!innamic acid3 .... 36 
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Cinnamate-4-hydroxylase (C4H) catalyses oxidation of trans-cinnamic acid at the 
para-position. This reaction requires NADPH and molecular oxygen and exhibits 
properties characteristic of plant P450 enzymes.34-36 In this reaction mechanism the 
proton at the 4-position is oxidised to a hydroxyl group and in the process moved to 
the 3-position. This shift was established by tritium-labelling experiments performed 
at the National Institute of Health at New Bethesda Hospital, Washington D.C. and is 
thus called the NIH shift.9,34-36 (Scheme 2.7) 
~hYdridemigration ~ I NIH shift I ,. EB ,. R H ~ R H 
08 0 
-Iff> / '" _REB 
/ enolization ~ 
lossoflabelled ~I retention of ~I 
hydrogen ~ labelled ~ 
R hydrogen H 
OR OR 
Scheme 2.7: Mechanism ofthe NIH shift 9 
The p-coumaric acid is then converted to p-coumaryl-CoA by the enzyme 4-





4-coumarate: C~A ligase 
HO 
Figure 2.16: Conversion of 4-coumaric acid to 4-coumaryl CoA 
SCoA 
In the next step three malonyl-CoA molecules combine with p-coumaryl-CoA to give 
the polyketide ester. The result is the elongation of the aliphatic side chain of 4-
coumarate by six carbon atoms. Cyclization of the polyketide ester via a postulated 
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Claisen-type reaction produces the tetrahydroxychalcone. This step is catalysed by the 













Scheme 2.8: The biosynthesis of 2',4' ,6' ,4- tetrahydroxychalcone34-36 
OH 
OH 
As already mentioned, chalcones are the intermediates to all flavonoids. Since 
chalcone formation is catalysed by chalcone synthase, this enzyme may be regarded 
as the most essential enzyme in flavonoid biosynthesis. Generally, methionine is often 
the source of an additional carbon in many biosynthetic pathways. In this case the 
2',4',6',4-tetrahydroxychalcone IS converted to the 2'-methoxy-4',6',4-
trihydroxychalcone with S-adenosylmethionine. The reaction is catalysed by the 
enzyme, methyl transferase. 
HO OH HO OH 
S-adenosylrnethionine -methyl transferase 
OH 0 OH 0 
2',4',6',4-tetrahydroxychalcone 4',6',4-tetrahydroxy-2'-methoxychalcone 
Figure 2.17: Formation of 4',6' ,4-tetrahydroxy-2'-methoxychalcone34-36 
A scheme for the conversion of chalcones to homoisoflavanoids has been proposed by 
Dewick.
2o 
It is believed that oxidation of the 2'-methoxy group, followed by 
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cyc1ization of the intennediate produces the three basic types of homoisoflavonoids. 
The ;ddition of a hydride ion leads to fonnation of 3-benzyl-4-chromanones while 
loss of a proton produces the 3-benzylidenyl-4-chromanone types. Hydration of 3-
benzylidenyl-4-chromanone or hydroxylation of 3-benzyl-4-chromanone produces 3-
benzyl-3-hydroxy-4-chromanones.2o The postulated mechanism is given in Scheme 
2.9. 
HO OR HO 
oxidation of :.. 
2'-methoxy 
OH 0 OH 0 
! 
HO OR HO 
.. loss ofa 
proton 
OH 0 HO 0 
3-benzylidenyl-4-cbromanone ~ 
-H,O f! +H,O [0] ! "'ditioo of hydride ion 
HO OR HO OR 
[H] ~ 
.. [0] 
OH 0 OH 0 
3-benzyl-3-bydroxy-4-cbromanone 3-benzyl-4-cbromanone 
Scheme 2.9: Postulated biosynthetic routes for the conversion of chalcones to 
homoisoflavonoids2O 
The more unusual homoisoflavonoids, scillascillin, brazil in and haematoxylin are 
thought to be derived from more complex mechanisms. The precursor to scillascillin 







Scheme 2.10: Proposed biosynthetic route to scillascillin type homoisoflavonoids10 
For brazilin and haematoxylin the mechanism is thought to be similar except that the 






Scheme 2.11: Proposed biosynthesis ofbrazilin type homoisoflavonoids10 
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2.6. Biological Activity of Homoisoflavonoids 
Homoisoflavonoids are known to be concentrated in the waxy, scale-like layers of 
bulbs.28 In this investigation homoisoflavanones were isolated from the bulb extracts. 
Homoisoflavonoids have been reported to have anti-inflammatory, antimutagenic, 
antibacterial and anti oxidative properties and this may be related to the medicinal use 
of plants that contain them.23,28,37,38,39 
There has been evidence to show that two closely related homoisoflavonoids intricatin 
and intricatinol isolated from the roots of Hoffmanosseggia intricata (Fabaceae) 
possess antimutagenic properties. They inhibit the mutagenicity of the carcinogens 2-
aminoanthracene, acetylaminofluorene and ethyl methane sulfonate in Salmonella 
typhimurium. Intricatinol is the more active homoisoflavonoid and it is believed that 





Figure 2.18: Structures of intricatin and intricatinol 
The homoisoflavonoid R-( -)-3-( 4-hydroxybenzyl)-5-hydroxy-6, 7 ,8-trimethoxy-
chroman-4-one from the bulbs of Veltheimia viridifolia was put through screening 
tests. This compound was first tested against phosphodiesterase (PDE) isoenzymes 
and shown to possess a weak selective profile for PDE IV and V. In vitro tests 
concerned with the inhibition of A 23187-stimulated leukotriene synthesis in human 
polymorphonuclear leucocytes showed weak activity. The homoisoflavanone was also 
tested for in vivo activity on respiration and the influence on the cardiac system of 
guinea pigs. It was found that after administration, expiratory flow increased slightly 
and there was an increase in the respiratory rate. Also, bronchoplasmolysis was 
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detected as well as a decrease in the heart rate. It was concluded that this compound 
has only weak and especially short biological activity in this in vivo test system.38 
The anti-inflammatory activity of bulbs within the Hyacinthaceae has been studied. 
The crude extracts of the bulbs of Muscari comosum, rich in homoisoflavonoids, have 
shown to inhibit croton oil-induced dermatitis in mouse ear as effectively as the 
potent anti-inflammatory drug, indomethacin.39 
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CHAPTER 3: THE OCCURRENCE AND BIOSYNTHESIS 
OFLIGNANS 
3.1. Introduction 
Lignans are naturally occurring dimers ofphenylpropanoid (C6-C3) units linked by the 
central carbons of their side chain.! Lignan precursors are substituted cinnamic 
alcohols that are joined by Cg-Cg' linkages, the most important of which are 4-
hydroxycinnamyl alcohol, coniferyl alcohol and sinapyl alcohol.!' 2 
OR 
i. 4-hydroxycinnamyl alcohol R1=H; R2=H 
ii. coniferyl alcohol R1=OCH3; R2=H 
iii. sinapyl alcohol R1=OCH3; R2=OCH3 
Figure 3.1: Structures of lignan precursors 
Lignans have been reported to occur in all parts of the plant. They are important 
constituents of the wood and have also been found in the roots, leaves, fruits, flowers 
and seeds.! 
A broad range of lignans have been identified, which is attributed to the great 
diversity in the chemical assembly of the two characteristic phenylpropanoid groups, 
as well as the degree of oxidation and the types of substituents.! 
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Figure 3.2: Examples of the structural diversity in Iignans showing Ca-Ca'linkages
3 
3.2. Biosynthesis of Lignans 
Biosynthesis of lignans begins with elimination of ammonia from the side chain of L-
phenylalanine to generate the appropriate trans-cinnamic acid. This is achieved via 
the enzyme phenylalanine ammonia lyase (PAL). Various derivatives of cinnamic 
acid are formed by further hydroxylation and methylation reactions, sequentially 
building up the substitution pattern typical of the shikimate pathway metabolites i.e. 
an ortho oxidation pattern (Scheme 3.1). 2 
~a~:!:~~&·on CO~H2 6C02H 
::rl~::rl 
~ ~ 
L-Phe cinnamic acid 
NA~;H 1 hydroxylation 
L-Phe = L-phenylalanine 
NADPH = nicotinamide adenine dinucleotide phosphate 













Scheme 3.1: Shikimate pathway showing formation of various cinnamic acid derivatives1 
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The next step in the biosynthesis is the fonnation of hydroxycinnamyl alcohol 
monomer units. This involves the reduction of the corresponding cinnamic acids via 
coenzyme A esters and aldehydes. Fonnation of the coenzyme A ester facilitates 
reduction to the aldehyde by introducing a better leaving group (CoAS) for the 
NADPH-dependent reaction. Reduction of the aldehyde to the phenolic monomer 
utilizes a further molecule ofNADPH and is a reversible reaction (Scheme 3.2).2 
C02H COSCoA CHO CH20H 
.0 
HSCo:\. NADPH NADPH • ... "' 
RI R2 RI R2 RI R2 RI R2 
OH OH OH 
RI, R2= R, OR, OCR3 
Scheme 3.2: Formation of phenolic monomers from cinnamic acid derivatives2 
Phenolic oxidative coupling of alcohol monomers catalysed by peroxidase enzymes 
fonn lignans. The peroxidase enzyme generates a free radical species. One electron 
oxidation of a simple phenol allows delocalization of the unpaired electron, giving 
resonance fonns in which the free electron resides at positions ortho and para to the 
oxygen function. Conjugation also allows the unpaired electron to be delocalized to 
the side chain (Scheme 3.3). Radical pairing of the resonance structures, cyc1ization 


















































Scheme 3.3: Formation oflignans from phenolic monomers1 
It was initially believed that coupling of phenolic monomer radicals to form lignans is 
random, requiring enzymes only to generate the corresponding free radicals. Random 
coupling, however, could not explain the optically active lignans found in nature. The 
discovery of dirigent (guiding) proteins gave a new perspective to the mechanism 
involved in lignan biosynthesis.4 
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This protein shows no catalytic activity but has sites that bind either the monomers or 
monomer radicals in specific orientations that lead to specific coupling.4,5,6 The 
dirigent protein was first isolated from Forsythia intermedia, a plant that both 
produces and further metabolizes the enantiomerically pure lignan, (+ )-pinoresinol 
which is formed from (E)-coniferyl alcohol monomers. It was found that an in vitro 
system containing the protein, an oxidant and (E)-coniferyl alcohol monomers 
produced (+)-pinoresinol in almost 100% optical purity while a system with only an 
oxidant and the monomer gave racemic mixtures of random coupling products.4 
How the protein binds and orientates the substrate is somewhat unclear. The dirigent 
protein controls the monomers that will be incorporated and the type of linkage 
formed through specificity and orientations of the binding sites. Kinetic studies 
suggest that the protein functions in a unique manner, whereby the peroxidase first 
generates the free-radical intermediate, which is then presumed to capture the dirigent 
protein. These are bound and orientated in such a manner that coupling can provide 
only an optically pure product. 5,6 
Little is known about the mechanism for the stereo selectivity and enantiospecificity in 
lignan formation. The enantiomeric composition of a particular lignan may vary with 
the plant species. Forsythia suspensa produces (+)-pinoresinol while Zanthoxylum 
ailanthoides produces ( -)-pinoresinol. It was found that species of the genera 
Forsythia, Arctium and Wikstroemia accumulate different enantiomers with various 
enantiomeric compositions.3 
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3.3. Biological Activity of Lignans 
Lignans have been found to have a broad range of uses, particularly in human health 
where their biological activities have come to be appreciated only fairly recently. 
Their beneficial cardioprotective, antiviral, antibacterial, antifungal and anticancer 
properties have been reviewed.7 
Investigations into the biological activity of lignans have led scientists to believe that 
lignans interfere with estrogen metabolism and may be significant in combating the 
onset of hormone dependent cancers such as breast, endometrium and prostate 
cancers. The estrogenic effects of lignans have also been associated with the 
prevention of bone resorption and promotion of increased bone density, thus 
preventing beginning of osteoporosis.7 
Podophyllotoxin, a constituent of Podophyllum pe/tatum, has been identified for its 
antitumor activity as a result of screening for cytostatic activity. It is used to treat 
venereal warts and is a precursor to the drug etoposide, which is used to treat 
testicular cancer. Secoisolariciresinol, secoisolariciresinol diglucoside, and 
matairesinol are the chemopreventive agents of many edible plants and their 
metabolism in the gut helps protect against the onset of breast and prostate cancers.6 
Lignans have also been tested for cardioprotective benefits and the lignan 
cinnamophilin has been studied for the ability to reduce platelet aggregation and 
vasoconstriction.8 Gomisin A from the plant Schisandra chinensis is used in the 
treatment of liver disorders and kadsurenone from Piper Jutokadsura is a platelet-
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CHAPTER 4: EXTRACTIVES FROM EUCOMIS 
MONTANA 
4.1 Introduction 
This is the first reported phytochemical study of Eucomis montana. The 
dichloromethane, ethyl acetate and the methanol extracts were investigated. This has 
led to the isolation of one nortriterpenoid and four homoisoflavonoids from the 
dichloromethane extract, five homoisoflavonoids from the ethyl acetate extract and 
two homoisoflavonoids from the methanol extract. The compounds isolated were 
(1) (23S)-17a,23-epoxy-3~,28,29-trihydroxy-27-nor1anost-8-en-24-one, (2) 4'-
demethyl-3,9-dihydroeucomin (5,7-dihydroxy-3-(4'-hydroxybenzyl)-4-chromanone), 
(3) 3,9-dihydroeucomin (5,7-dihydroxy-3-(4'-methoxybenzyl)-4-chromanone), (4) 4'-
demethyl-5-0-methyl-3,9-dihydroeucomin (7-hydroxy-3-(4'-hydroxybenzyl)-5-
methoxy-4-chromanone, (5) 8-0-demethyl-7 -O-methyl-3 ,9-dihydropunctatin (5,8-
dihydroxy-3-(4'-hydroxybenzyl)-7-methoxy-4-chromanone), (6) 7-0-methyl-3,9-
dihydropunctatin (5-hydroxy-3-( 4'-hydroxybenzyl)-7 ,8-dimethoxy-4-chromanone), 
(7) 7 -hydroxy-3-( 4'-hydroxybenzyl)-5 ,6-dimethoxy-4-chromanone, (8) 3,5,7-
trihydroxy-3-( 4'-hydroxybenzyl)-4-chromanone, (9) eucomol (3,5,7 -trihydroxy-3-( 4'-
methoxybenzyl)-4-chromanone, (10) 7 -O-methyleucomol (3,5-dihydroxy-7 -methoxy-
3-(4'-methoxybenzyl)-4-chromanone), (11) (E)-eucomin «E)-5,7-dihydroxy-3-(4'-
methoxybenzylidenyl)-4-chromanone) and (12) 3',5,7 -trihydroxy-4'-methoxyspiro-
[2H-l-benzopyran-3(4H),7'-bicyc10[4.2.0]octa[1,3,5]-trien]-4-0ne. Of these twelve 
compounds 7-hydroxy-3-(4'-hydroxybenzyl)- 5,6-dimethoxy-4-chromanone has not 









H H H H 
HO~*OCH' HO 
OH 
~ # H 
H H H H 
OH 0 
(3) 
H OCH3 O H 
OH H H 
H3CO OH H3CO OH 
H H H 
OH 0 H 
(5) 
OH . 0 H 
(6) 
H H H H 
HO OH HO OH 
H3CO H H H 
OCH3 O H OH H 
(7) 
H H H H 
HO OCH3 H3CO OCH3 
H H H H 
OH 0 H OH 0 H 
(10) 
H 
H H HO 
HO OCH3 OCH3 
H 
H H OH 
OH 0 H H 
Figure 4.1: Compounds isolated from Eucomis montana 
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4.2. Results and Discussion 
4.2.1. Structural elucidation of compound 1: (23S)-17«,23-epoxy-3p,28,29-
trihydroxy-27-norlanost-8-en-24-one (spectra 1-1.9, pp 143-152) 





Figure 4.2: Structure of compound 1: (23S)-17a,23-epoxy-3p,28,29-trihydroxy-27-norlanost-8-
en-24-one 
Compound 1 was found to belong to the class of compounds known as eucosterol-
type nortriterpenoids. The high resolution mass spectrum [spectrum 1.8] showed a 
molecular ion [Ml peak at mlz 474.33398 which corresponded to a molecular 
formula of C29I4605. From this, a double bond equivalence of seven was deduced. 
The IH NMR spectrum [spectrum 1.1] showed a multiplet at OH 3.74 attributed to H-
3 and its corresponding carbon resonance occurred at oe 77.6 in the l3C NMR 
spectrum [spectrum 1.2]. The IH NMR spectrum also showed a pair of doublet 
resonances at OH 3.76 and OH 4.34 (d, J = 11.6 Hz) belonging to the methylene protons 
of2H-29. The other pair of doublet resonances at OH 3.76 and OH 4.14 (d, J= 11.2 Hz) 
was assigned to 2H-28 because the HMBC spectrum [spectrum 1.5] showed a 
correlation between C-3 and C-5 and these resonances. This indicated that the methyl 
group at C-28 was oxidised to an alcohol. The H-23 resonance occurred as a double 
doublet downfield at OH 4.50 (dd, J = 10.4, 7.3 Hz). 
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The lH NMR spectrum showed the presence of five methyl groups. Of these, three 
were tertiary methyl groups: 3H-18 (OH 0.86), 3H-19 (OH 0.92) and 3H-30 (OH 1.19). 
These were assigned using the HMBC spectrum. The methyl group protons at C-18 
were assigned because the HMBC spectrum showed a correlation from C-17 to the 
methyl group proton singlet at OH 0.86. A correlation from C-9 to the methyl group 
proton singlet at OH 0.92 allowed assignment of the methyl group protons at C-19. The 
HMBC spectrum showed a correlation from C-8 to the methyl group proton singlet at 
OH 1.19 and this methyl group proton resonance was assigned to 3H-30. The 
remaining two methyl group protons were difficult to distinguish because they were 
both superimposed at OH 1.04 in the HSQC spectrum [spectrum 1.4]. A correlation of 
C-22 with the 3H-21 resonance and C-25 with the 3H-26 resonance in the HMBC 
spectrum allowed assignment of the methyl groups at C-21 and C-26. Their 
corresponding carbon resonances occurred at Oc 17.1 and Oc 7.4 respectively in the 
l3C NMR spectrum. 
The l3C NMR spectrum showed the presence of twenty-nine carbon signals, which 
were resolved by the ADEPT spectrum [spectrum 1.3] into five methyl, twelve 
methylene and four methine groups. This indicated that there were eight fully 
substituted carbon atoms. The low field shifts at Oc 133.9 and Oc 135.2 were assigned 
to the two quaternary carbons of the double bond, C-8 and C-9 respectively. These 
were assigned accordingly because the resonance at Oc 133.9 showed an HMBC 
correlation with 3H-30 and the resonance at Oc 135.2 showed HMBC correlations to 
H-5 and 3H-19. 
The mass spectrum showed a peak at mlz 417.29715 that resulted from elimination of 
an ethyl ketone radical (M+ -57). This allowed placement of the ketone group 
resonating at Oc 213.7 to the C-24 position. HMBC correlations between C-24 and the 
2H-25 and 3H-26 proton resonances confirmed placement of the ketone group at the 
C-24 position. The fifth oxygen atom indicated by the molecular formula was placed 
between C-17 and C-23. This was determined by the presence of the two further 
signals at Oc 97.0 and Oc 81.4 attributed to C-17 and C-23 in addition to the three 
carbinolic carbon resonances in the l3C NMR spectrum. I The pentacyc1ic ring 
structure accounted for the five remaining double bond equivalents. 
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The NOESY spectrum [spectrum 1.7] was used to detennine the stereochemistry of 
the compound. NOESY correlations between H-23, H-22u and 3H-21 indicated that 
H-23 was u. No correlations between H-5 and H-19 could be seen which indicated 
that H-19 was ~ as expected. The 3H-21 and 3H-18 resonances showed correlations 
with each other due to the C-17, C-20 bond being ~. 
The infrared spectrum [spectrum 1.9] showed a broad signal at 3421 cm-1 due to 
hydroxy group stretching and the strong peak at 1737 cm-1 indicated the presence of a 
ketone carbonyl group. The peak observed at 2934 cm-1 was due to aliphatic C-H 
stretching. 
Finally, a literature search for the proposed structure was undertaken and it was found 
that \3C NMR data of compound 1 compared favourably with that of (23S)-17a,23-
epoxy-3p,28,29-tribydroxy-27-norlanost-8-en-24-one. Table 4.2 shows this comparison. 
This compound has been previously isolated from Muscari comosum and Ledebouria 
zebrina. 1•2 
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Table 4.1: I H , l3C, HMBC, COSY and NOESY data for compound 1 (CDCh) 
IH/ppm l3CI HMBC COSY NOESY 
ppm C~H 
1 1.71 m 35.1 3H-19 2H-2 
2 1.76m 27.3 2H-l H-3 3H-19 
3 3.74m 77.6 H-28a,b, H- 2H-2 H-28b, H-5 
29a,b 
4 45.8 H-5 
5 1.23 m 47.0 3H-19, H-3, H- 2H-6 2H-7, H-28a 
28a,b, H-29a,b 
6 1.46m 18.6 
7 1.98 m 26.1 H-5,3H-30 
8 133.9 3H-30 
9 135.2 H-5,3H-19 
10 36.6 H-5, 3H-19 
11 a-2.15 m 20.7 H-12a,p, H-llP 
/3-1.95 m H-12a,/3, H-lla 3H-19,H-12a,/3 
12 a-1.38 m 24.8 3H-18 H-lla,p, H-12P 3H-21 
/3-2.18 m H-lla,/3, H-12a 3H-18 
13 48.5 3H-18,3H-30 
14 50.4 3H-18, 3H-30 
15 a-1.61 m 31.6 3H-30 H-16a,p, H-15P 3H-30 
/3-1.33 m H-16a,/3, H-15a H-16/3 
16 a-2.15 m 39.6 H-15a,p, H-16P 3H-30 
P-1.61 m H-15a,p, H-16a 3H-21, H-20, 3H-
18, H-15J3 
17 97.0 H-15p, 3H-18, 
3H-21,2H-22 
18 0.86 s 19.4 3H-21 3H-21, H-15p, H-
20, H-12/3, H-16/3 
19 0.92 s 19.1 2H-2 2H-l, 2H-7, H-
29b 
20 2.16s 43.5 3H-21 3H-21 3H-18, 3H-21, H-
1613 
21 1.03 d, 7.1 17.1 2H-22 H-20 3H-18, H-23, H-
12/3,2H-22 
22 1.76m 36.7 3H-21 H-23 3H-21, H-23 
23 4.50 dd, 10.4, 81.4 2H-22 2H-25,3H-21, 
7.3 2H-22 
24 213.7 3H-26, 2H-25 
25 2.52 q, 7.33 32.3 3H-26 3H-26 H-23,3H-26 
26 1.04 t* 7.4 2H-25 2H-25 2H-25, H-23 
28 a-3.76 d, 11.2 70.8 H-5, H-29b H-29b H-29a,b, H-5 
b-4.14 d, 11.2 H-29a H-3 
29 a-3.76 d, 11.6 63.7 H-3, H-5 H-29b H-28b 
b-4.34 d, 11.6 H-28a- 3H-19, H-29a 
30 1.19 s 25.8 3H-18 H-15a, H-16a 
* Peaks obscured, J values could not be determined 
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Table 4.2: Comparison of 13C NMR data for compound 1 and (23S)-17a,23-
epoxy-3P, 28,29-trihydroxy-27-norlanost-8-en-24-one 
13C NMR data of compound 1 J3C NMR data from 
(CDCh)/ppm literature (CDCh)l/ ppm 
1 35.1 35.3 
2 27.3 27.5 
3 77.6 77.9 
4 45.8 46.0 
5 47.0 47.3 
6 18.6 18.7 
7 26.1 26.2 
8 133.9 134.1 
9 135.2 135.5 
10 36.6 36.5 
11 20.7 20.8 
12 24.8 24.9 
13 48.5 48.7 
14 50.4 50.6 
15 31.6 31.7 
16 39.6 39.7 
17 97.0 97.2 
18 19.4 19.5 
19 19.1 19.2 
20 43.5 43.6 
21 17.1 17.2 
22 36.7 36.8 
23 81.4 81.5 
24 213.7 213.6 
25 32.3 32.3 
26 7.4 7.4 
28 70.8 71.3 
29 63.7 63.8 
30 25.8 25.9 
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4.2.2. Structural elucidation of compound 2: 4'-demethyl-3,9-dihydroeucomin 
(spectra 2.1-2.12, pp 153-163) 
This compound was isolated as a yellow, crystalline solid with a melting point of 96-
99 ·C. 
H H 
HO o 2 H OH 
3 
H H 9 
OH 0 H 
Figure 4.3: Structure of compound 2: 4'-demethyl-3,9-dihydroeucomin 
The low resolution mass spectrum [spectrum 2.11] gave a molecular ion [M+] peak at 
mlz 286. This corresponded to a molecular formula of C16H140S, from which a double 
bond equivalence of ten was deduced. The compound gave UV absorption maxima at 
324 nm (log E 4.00),267 nm (log E 4.46) and 238 nm (log E 4.76) [spectrum 2.8]. 
The IH NMR spectrum [spectrum 2.1] of compound 2, showed a typical splitting 
pattern for the 2H-2, H-3 and 2H-9 protons. The pair of double doublet resonances at 
OH 4.07 (dd, J = 11.4 and 7.1 Hz) and OH 4.23 (dd, J = 11.4 and 4.4 Hz) ascribed to 
H-2a and H-2b respectively, the multiplet resonance at OH 2.77 ascribed to H-3, and a 
pair of double doublet resonances at OH 3.08 (dd, J = 13.7 and 4.6 Hz) and OH 2.63 
(dd, J= 13.7 and 10.3 Hz) assigned to H-9a and H-9b are characteristic of3-benzyl-4-
chromanone type homoisoflavonoids. 
The H-2a proton resonance was split into a double doublet because of coupling with 
the H-3 and H-2b protons. The resonances for H-2b, H-9a and H-9b were split into 
double doublets in the same manner. The H-3 proton resonance was split into a 
multiplet because this proton is coupled to the H-2a, H-2b, H-9a and H-9b protons. 
The resonances for the H-2 protons were more deshielded and shifted downfield 
because the methylene group was attached to an oxygen atom. The COSY spectrum 
[spectrum 2.6] showed coupling between 2H-2 and H-3, and then H-3 with 2H-9, 
which confirmed assignment of these protons. The l3C NMR resonances for C-2, C-3 
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and C-9 occurred at Oc 70.1, Oc 48.1 and Oc 33.0 respectively [spectrum 2.2]. The 
absolute stereochemistry at C-3 can only be determined with circular dichroism 
techniques. Future work requires collaboration with other institutes to determine this. 
The carbon resonance at Oc 199.5 was ascribed to the carbonyl group at C-4 as this 
resonance showed correlations to the 2H-9, H-3 and 2H-2 resonances in the HMBC 
spectrum [spectrum 2.5]. 
An A-4 type cleavage of the molecular ion (mlz 286) resulted in the chromanone 
fragment at mlz 179 represented in Scheme 4.1. The occurrence of peaks at mlz 152 
and 153 in the mass spectrum was due to a retro-Diels-Alder (RDA) cleavage and 
hydrogen-shift of the chromanone fragment. This indicated the presence of two 
hydroxy groups on ring A. The A-4 type fragmentation pattern is common for 3-
benzyl-4-chromanone type homoisoflavonoids. The hydroxytropylium peak at mlz 
107 indicated the presence of one hydroxy group on the Bring. 
HO OH + HOW' OOH ~ I + 
~ H H2C 
HO 0 HO 0 
mlz 286 mlz 179 mlz 107 
m/z 152 mlz 153 
Scheme 4.1: Mass spectral fragmentation pattern for compound 2 
The substitution pattern on the A-ring was determined using the IH NMR, UV and 
mass spectra. The pair of doublets at OH 5.87 (J = 2.2 Hz) and OH 5.84 (J = 2.2 Hz) 
indicated meta-coupled protons: the H-6 and H-8 protons respectively (see Section 
2.4). Their corresponding carbon resonances occurred at Oc 97.1 and Oc 95.8 in the 
l3C NMR spectrum. The HMBC spectrum showed a correlation between the 
resonance at OH 5.84 and the C-8a resonance, which distinguished H-8. The remaining 
doublet was therefore that of H-6. The carbon resonance at Oc 164.7 was assigned to 
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C-8a because it showed HMBC correlations to the 2H-2 protons. Bathochromic shifts 
with AICh (+20 nm) and NaOAc (+36 nm) in the UV spectrum [spectra 2.9 and 
2.10] indicated hydroxy groups at the C-5 and C-7 positions.3 The deshielded carbon 
resonances of C-5 and C-7 at ()c 165.8 and ()c 168.2 were assigned to their respective 
positions because of correlations of C-5 with H-6 and C-7 with H-6 and H-8 in the 
HMBC spectrum. 
The pair of doublet resonances at ()H 6.73 (J = 8.6 Hz) and ()H 7.05 (J = 8.6 Hz), each 
integrating to two protons, were typical resonances of a para-disubstituted aromatic 
ring system. These resonances were assigned to the H-3 '/5 , and H-2'/6' protons 
respectively of the B ring. The HMBC spectrum showed a correlation between the 
methine resonance at ()H 7.05 and C-9 and was therefore assigned H-2'/6'. The 
remaining doublet resonance had to be that ofH-3'/5'. The resonance at ()c 157.2 was 
assigned to C-4' because of correlations with the H-2'/6' and H-3'/5' protons in the 
HMBC spectrum. A hydroxy group indicated by the hydroxytropylium ion in the 
mass spectrum was placed at the C-4' position because the B ring was para-
substituted. The resonance at ()c 130.2 was assigned to C-l' because it showed a 
HMBC correlation to H-9a,b and H-3'/5'. 
The IR spectrum [spectrum 2.12] further supported the proposed homoisoflavonoid 
structure. Peaks were observed at 3374 cm-! (O-H stretching), 2920 cm-! (aliphatic C-
H stretching), 1641 cm-! (C=O stretching), 1520 cm-! (aromatic C=C stretching). 
Finally, a literature search for compound 2 was undertaken. By comparison of the !H 
and \3C NMR data (Tables 4.4 and 4.5) it was found that compound 2 was the known 
compound 4' -demethyl-3,9-dihydroeucomin (or 5,7 -dihydroxy-3-( 4' -hydroxy-
benzyl)-4-chromanone) which has been previously isolated from Muscari comosum 
and Ledebouria ovatijolia.3,4,5 
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Table 4,3: IH, l3C, HMBC, COSY and NOESY data for compound 2 (CD30D1 
IH/ "'C/ HMBC COSY NOESY 
ppm ppm C-+H 
2 a-4.07 dd, 70.1 H-9a,b H-3 H-3, H-9a, H-2b 
11.4, 7.1 
b-4.23 dd, H-3, H-2a, H-2'/6' 
11.4,4.4 
3 2.77m 48.1 H-9a,b, H-2a H-9a,b, H- H-9b, H-2a,b, H-
2a,b 2'/6' 
4 199.5 H-2a,b, H-3, H-
9a,b 
4a 102.8 H-6, H-8 
5 165.8 H-6 
6 5.87 d, 2.2 97.1 H-8 H-8 
7 168.2 H-8, H-6 
8 5.84 d, 2.2 95.8 H-6 H-6 
8a 164.7 H-2a,b, H-8 
9 a-3.08 dd, 33.0 H-2a,b, H-3, H- H-3, H-9b H-9b, H-2'/6' 
13.7,4.6 2'/6' 
b-2.63 dd, H-3, H-9a H-9a, H-3, H-2'/6' 
13.7,10.3 
l' 130.2 H-3'/5', H-9a,b 
2'/6' 7.05 d, 8.6 131.1 H-9a,b H-3'/5' H-2a, H-3, H-9a,b, 
H-3'/5' 
3'/5' 6.73 d, 8.6 116.4 H-2'/6' H-2'/6' H-2'/6' 
4' 157.2 H-2'/6', H-3'/5' 
Table 4.4: Comparison ofthe IH NMR data for compound 2 with 4'-demethyl-
39 d'h d ' 4 , - I Iyl roeucomm 
IH NMR data for compound 2 IH NMR data from literature 
(CD3OD)lppm lCD30Dt/ ppm 
2 a-4.07 dd, 11.4, 7.1 a-4.08 dd, 11.4, 7.3 
b-4.23 dd, 11.4, 4.4 b-4.25 dd, 11.4, 4.4 
3 2.77m 2.79m 
6 5.87 d, 2.2 5.87 d, 2.1 
8 5.84 d, 2,2 5.85 d, 2.1 
9 a-3.08 dd, 13.7,4.6 a-3.04 dd, 13.4, 3.8 
b-2.63 dd, 13.7, 10.3 b-2.65 dd, 13.4, 10.4 
2'/6' 7.05 d, 8.6 7.06 d, 8.2 
3'/5' 6.73 d, 8.6 6.74 d, 8.2 
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Table 4.5: Comparison of I3C NMR data for compound 2 with 4'-demethyl-3,9-
dOh d 0 4 l1Y' roeucomm 
BC data of compound 2 TIC data from literature 
(CD30D)I ppm (CD30D)4/ ppm 
2 70.1 70.1 
3 48.1 48.2 
4 199.5 199.4 
4a 102.8 102.8 
5 165.8 165.8 
6 97.1 97.1 
7 168.2 168.2 
8 95.8 95.9 
8a 164.7 164.6 
9 33.0 32.9 
l' 130.2 130.2 
2'/6' 131.1 131.2 
3'/5' 116.4 116.4 
4' 157.2 157.2 
67 
4.2.3. Structural elucidation of compound 3: 3,9-dihydroeucomin (spectra 3.1-
3.12, pp 164-174) 




H H 9 2' H 
OH 0 H 
Figure 4.4: Structure of compound 3: 3,9-dihydroeucomin 
Compound 3 gave a UV absorption maximum at 293 nm (log E 4.24) [spectrum 3.8J. 
The mass spectrum [spectrum 3.11J gave a molecular ion [Ml peak at mlz 300 and 
this corresponded to a molecular formula of C17HI60 5. From this a double bond 
equivalence of ten was deduced. 
The IH NMR spectrum [spectrum 3.1J of compound 3 showed a characteristic 
splitting pattern for 3-benzyl-4-chromanone type homoisoflavonoids. These were the 
H-2a and H-2b double doublet resonances at oH4.06 (dd, J= 11.4,6.5 Hz) and oH4.22 
(dd, J = 11.4, 4.0 Hz), the multiplet resonance of H-3 at OH 2.74 and the pair of 
double doublet resonances ofH-9a and H-9b at oH2.67 (dd, J= 13.4, 10.6 Hz) and OH 
3.13 (dd,J= 13.4,3.9 Hz). 
The meta-coupled protons, H-6 and H-8 on the A-ring were indicated by the doublet 
resonances at OH 5.94 (J = 2.2 Hz) and OH 5.88 (J = 2.2 Hz) in the IH NMR spectrum. 
The peaks at mlz 153 and 179 in the mass spectrum indicated the presence of two 
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Scheme 4.2: Mass spectral fragmentation pattern for compound 3 
Bathochromic shifts of +32 run with AICh and +32 run with NaOAc [spectra 3.9 and 
3.10] were observed and this indicated hydroxy groups at the C-5 and C-7 positions.6 
The deshielded carbon resonances of C-5 and C-7 at Oc 164.4 and Oc 166.0 were 
assigned to their respective positions because of HMBC correlations of C-5 with H-6 
and C-7 with H-6 and H-8 [spectrum 3.5]. The broad singlet at OH 12.14 indicated the 
strongly hydrogen bonded proton of the hydroxy group at C_5.7 This was confirmed 
by the downfied shift of the C-4 resonance that occurred at Oc 197.5 in the I3C NMR 
spectrum [spectrum 3.2] due to the chelating effects of the C-5 hydroxy group with 
that of the carbonyl group. Placement of the hydroxy group at the C-7 position was 
confirmed by the presence of the C-6 and C-8 resonances at Oc 96.5 and Oc 95.2. If a 
methoxy group was attached to C-7 an upfield shift of 1.3 ppm and 3.3 ppm would 
have been observed for the C-6 and C-8 resonances in the I3C NMR spectrum.4 
The two proton doublet resonances at OH 6.83 (J = 8.6 Hz) and OH 7.11 (J = 8.6 Hz) in 
the IH NMR spectrum indicated apara-disubstituted B-ring system. These resonances 
were assigned to the H-3'/5' and H-2'/6' protons respectively. The methoxy group, 
indicated by a proton resonance at OH 3.76 integrating to three protons, was placed at 
the C-4' position because of a NOESY interaction with the H-3'/5' protons in the 
NOESY spectrum [spectrum 3.7]. This was further supported by the presence of an 
intense peak at m/z 121 in the mass spectrum that corresponded to a 
methoxytropylium ion. 
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The IR spectrum [spectrum 3.12] showed peaks typical of homoisoflavonoids. These 
were observed at 3364 cm-1 (O-H stretching), 2929 cm-1 (aliphatic C-H stretching), 
1644 cm-1 (C-O stretching) and 1515 cm-1 (aromatic C=C stretching). 
Finally, a literature search was undertaken for compound 3 and it was found that the 
IH NMR data (Table 4.7) matched that of the known compound 3,9-dihydro-
eucomin (or 5,7 -dihydroxy-3-( 4' -methoxybenzyl)-4-chromanone), previously 
isolated from Eueomis bieolor.8 
Table 4.6: H, 13 C, HMBC, COSY and NOESY data for compound 3 (CDCh) 
IH/ppm 13C/ HMBC COSY NOESY 
ppm C-+H 
2 a-4.06 dd, 11.4, 68.8 H-3, H-9a,b H-2b, H- H-9a, H-2b 
6.5 3 
b-4.22 dd, 11.4, H-2a, H- H-9a, H-2a 
4.0 3 
3 2.74m 46.8 H-9a,b, H-2b H-9a,b H-9b, H-
2a,b 
4 197.5 H-9a,b, H-3, H-
2a,b 
4a 102.0 H-8, H-6 
5-0H 12.14 bs 164.4 H-6 
6 5.94 d, 2.2 96.5 H-8 
7 166.0 H-6, H-8 
8 5.88 d, 2.2 95.2 H-6 
8a 163.1 H-2a,b, H-8 
9 a-2.67 dd, 13.4, 32.0 H-3, H-2a,b, H- H-9b, H- H-2a, b 
10.6 2'/6' 3 
b-3.13 dd, 13.4, H-9a, H- H-3 
3.9 3 
l' 129.8 H-9a,b, H-3, H-
3'/5',H-2'/6' 
2'/6' 7.11 d,8.6 130.0 H-3'/5',H-9a,b H-3 '/5 , 
3'/5' 6.83 d, 8.6 114.1 H-2'/6' H-2'/6' 4'-OCH3 
4' 158.3 4'-OCH3, H-3'/5', 
H-2'/6' 
4'-OCH3 3.76 s 55.4 H-3'/5' 
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Table 4.7: Comparison of IH NMR data for compound 3 and 3,9-dihydro-
eucomin8 
IH NMR data for compound 3 IH NMR data from literature 
. (CDCh)/ ppm (CDCh)8/ ppm 
2 a-4.06 dd, 11.4, 6.5 a-4.12 dd, 11.5, 6.5 
b-4.22 dd, 11.4, 4.0 b-4.28 dd, 11.5, 4.2 
3 2.74m 2.80m 
5-0H 12.14 bs 12.13 s 
6 5.94 d, 2.2 5.98 d, 2.3 
8 5.88 d, 2.2 5.91 d,2.3 
9 a-2.67 dd, 13.4, 10.6 2.80m 
b-3.13 dd, 13.4,3.9 3.20m 
2'/6' 7.11 d, 8.6 7.14 d, 8.8 
3'/5' 6.83 d, 8.6 6.86 d, 8.8 
4'-OCH3 3.76 S 3.80 s 
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4.2.4. Structural elucidation of compound 4: 4'-demethyl-5-0-methyl-3,9-
dihydroeucomin (spectra 4.1-4.13, pp 175-186) 
Compound 4 was isolated as a colourless crystalline solid with a melting point of 20 1-
203°C. 
H H 





H H 9 
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OCH3 O H 
Figure 4.5: Structure of compound 4: 4'-demethyl-5-0-methyl-3,9-dihydroeucomin 
This compound gave a molecular ion [Mj peak at mlz 300 in the mass spectrum 
[spectrum 4.12] that corresponded to a molecular formula of C17HI60S. From this a 
double bond equivalence of ten was deduced. UV absorption maxima were obtained 
at 283 nm (log E 2.83) and 232 nm (log E 3.77) [spectrum 4.9]. 
The IH NMR spectrum [spectrum 4.1] showed a splitting pattern for the C-2, C-3 and 
C-4 proton coupled system that was typical for the 3-benzyl-4-chromanone type 
homoisoflavonoids. These resonances were similar to those found in compound 2 and 
3. 
The IH NMR spectrum indicated meta-coupled protons at OH 6.09 (d, J = 2.2 Hz) and 
OH 5.98 (d, J = 2.2 Hz) attributed to H-6 and H-8 of the A ring. The UV spectrum 
[spectrum 4.11] showed a bathochromic shift (+20 nm) with NaOAc, which 
indicated the presence of a hydroxy group at the C-7 position. No shift was observed 
with AICh [spectrum 4.10] and this indicated that a hydroxy group was not present at 
C_5.9 The methoxy group indicated by the singlet resonance at OH 3.84 was placed at 
this position as this resonance showed a NOESY correlation to the H-6 proton in the 
NOESY spectrum [spectrum 4.8]. This was confIrmed by the appearance of the C-4 
carbonyl resonance at oe 194.0. It would be further downfIeld if a hydroxy group was 
present in the C-5 position due to its chelating effects.3 
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Substitution on the B-ring was the same as compound 2. The pair of doublets at OH 
7.07 (J= 8.6 Hz) and OH 6.75 (J= 8.6 Hz) were those of the respective H-2'/6' and H-
3'/5' protons which indicated apara-disubstituted aromatic ring system. 
The mass spectrum confirmed the substitution patterns on the A and B rings. The 
peak at m/z 193 was due to the A-4 type fragmentation and confirmed the presence of 
the methoxy and the hydroxy groups on the A ring while the peak at m/z 107, typical 
of the hydroxytropylium ion, confirmed the substitution pattern on the B ring. The 
peaks at m/z 166 and 167 are formed from the RDA cleavage and hydrogen-shift of 
the chromanone fragment. 
HO r' ° OR 
OCR) ° 
mlz 300 




mlz 193 mlz 107 
! RDA ~RDA & H-SHIFT 
Ro¥~t RO¥I OR 




mlz 166 mlz 167 
Scheme 4.3: Mass spectral fragmentation pattern for compound 4 
The IR data for compound 4 [spectrum 4.13] was consistent with that ofthe proposed 
structure. Peaks were observed at 3419 cm-! (O-H stretching), 2925 cm-! (aliphatic C-
H stretching), 1736 cm-! (C=O stretching) and 1590 cm-! (aromatic C=C stretching). 
A literature search for compound 4 showed that the !H NMR data (Table 4.9) agreed 
with that of 4'-demethyl-5-0-methyl-3,9-dihydroeucomin (or 7-hydroxy-3-(4'-
hydroxybenzyl)- 5-methoxy-4-chromanone). 6 This compound has been previously 
isolated from Eucomis hicolor and Eucomis punctata. 6,9 
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Table 4.8: IH, 13C, HMBC, COSY and NOESY data for compound 4 (CD30Dl 
lWppm 13C/ HMBC COSY NOESY 
ppm C--.H 
2 a-4.07 dd, 69.8 H-9a,b, H-3 H-3, H-9a, H-2b, H-2'/6', H-3, 
11.6,6.5 H-2b H-9a 
b-4.23 dd, H-9a, H-3, H-2a, H-3, H-9a 
11.6,3.8 H-2a 
3 2.65 m* 49.9 H-9a,b, H-2a,b H-9a,b, H- H-9b, H-2a,b, H-
2a,b, H-3 2'/6' 
4 194.0 H-9a,b, H-3, H-
2a,b 
4a 105.2 H-6, H-8 
5 164.5 5-0CH3, H-6 
6 6.09 d, 2.2 94.2 H-8 5-0CH3 5-0CH3 
7 166.5 H-6, H-8 
8 5.98 d, 2.2 96.7 H-6 
8a 166.7 H-2a,b, H-8 
9 a-2.65 m* 33.4 H-3, H-2a,b, H- H-3 H-9b 
2'/6' 
b-3.04 dd, H-3, H-9a H-9a, H-3, H-2'/6' 
11.0,4.8 
l' 130.6 H-9a,b, H-3, H-
2'/6', H-3'/5' 
2'/6' 7.07 d, 8.6 131.1 H-9a,b, H-3'/5' H-3'/5' H-3'/5', H-9a,b, H-
3, H-2a 
3'/5' 6.75 d, 8.6 116.3 H-2'/6' H-2'/6' H-2'/6' 
4' 157.1 H-2'/6', H-3'/5' 
5- 3.84 s 56.2 H-6 H-6 
OCH3 
* Peaks overlapping, not possible to determine coupling constants 
Table 4.9: Comparison of IH NMR data for compound 4 with 4'-demethyl-5-0-
h 139 d'h d • 6 met lyl- , - I l~ roeucomm 
IH NMR data for IH NMR data for IH NMR data from 
compound 4 compound 4 literature 
(CD30D)/ ppm «CD~2COJlj)pm 1(CD3)2CO)6/ ppm 
2 a-4.07 dd, 11 .6, 6.5 a-4.07 dd, 11.2, 8.2 a-4.06 dd, 11.2 
b-4.23 dd, 11.6, 3.8 b-4.27 dd, 11.2, 4.2 b-4.26 dd, 11.2 
3 2.65 m* 2.68m 2.2-3.5 m 
6 6.09 d, 2.2 6.15 d, 2.2 6.13 d, 2.3 
8 5.98 d, 2.2 6.02 d, 2.2 6.00 d, 2.3 
9 a-2.65 m* a-2.55 m 2.2-3.5 m 
b-3.04 dd, 11.0,4.8 b-3.03 m 
2'/6' 7.07 d, 8.6 7.11 d,8.4 7.09 d, 8.8 
3'/5' 6.75 d, 8.6 6.81 d, 8.4 6.79 d, 8.8 
5-0CH3 3.84 S 3.79 s 3.79 s 
* Peaks overlappmg, not possible to determme coupling constants 
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4.2.5. Structural elucidation of compound 5: 8-0-demethyl-7-0-methyl-3,9-
dihydropunctatin (spectra 5.1-5.14, pp 187-199) 







OH 0 H 
Figure 4.6: Structure of compound 5: 8-0-demethyl-7-0-methyl-3,9-dihydropunctatin 
Compound 5 showed a molecular ion [M+] peak at mlz 316 in the mass spectrum 
[spectrum 5.13). This corresponded to a molecular formula of C17H1606 from which 
a double bond equivalence of ten was deduced. UV absorption maxima were obtained 
at 368 nm (log E 3.13), 295 nm (log E 3.53) and 235 (log E 4.60) [spectrum 5.10). 
The IH NMR spectrum [spectrum 5.1) showed the characteristic 2H-2, H-3 and 2H-9 
resonances for a 3-benzyl-4-chromanone type homoisoflavonoid. This was similar to 
those of compounds 2-4. 
The singlet resonance at ()H 6.14 indicated a pentasubstituted A-ring system. The 
existence of a peak at mlz 209 in the mass spectrum was evidence for a dihydroxy-
methoxychromanone fragment ion. This indicated that the A-ring contained two 
hydroxy groups and one methoxy group. One hydroxy group was assigned to the C-5 
position due to a bathochromic shift (+14 nm) with AlCh in the UV spectrum 
[spectrum 5.11). This was confirmed by the downfield shift of the C-4 resonance at 
()c 200.1 in the l3C spectrum [spectrum 5.3) due to the chelating effects of the C-5 
hydroxy group with that of the carbonyl group. No shift was observed with NaOAc 
[spectrum 5.12) and this indicated the absence of a hydroxy group at the C-7 
position.3 The methoxy group indicated by the singlet resonance in the IH NMR 
















Scheme 4.4: Mass spectral fragmentation pattern for compound 5 
A NOESY correlation between the 5-0H proton resonance at OH 11.74 with the singlet 
resonance at OH 6.12 in the NOESY spectrum [spectrum 5.9] run in deuterated 
chloroform, indicated that the singlet resonance at OH 6.12 belonged to H-6. No 
HMBC correlation was seen between the C-8a resonance and this singlet resonance, 
which confirmed that it did not occur at C-8. The 5-0H proton and the methoxy group 
at the C-7 position showed NOESY correlations with the H-6 proton, confirming its 
assignment. Furthermore, the corresponding C-6 resonance occurred at an appreciably 
higher field at Oc 93.4 in the 13C NMR spectrum. This was attributed to the stronger 
electron-releasing effect of the 7-methoxy groUp.4 The second hydroxy group was 
then placed at the remaining C-8 position. 
Substitution on the B-ring was the same as compounds 2, 4 and 5 i.e. para-
disubstituted benzene ring with a hydroxy group attached at the C-4' position. The 
peak at mlz 107 in the mass spectrum indicated a hydroxytropylium ion that 
confirmed this assignment. 
The IR spectrum [spectrum 5.14] supported the proposed structure of compound 5. 
Peaks were observed at 3414 cm-1 (O-H stretching), 2920 cm-1 (aliphatic C-H 
stretching), 1652 cm-1 (C=O stretching) and 1514 cm-1 (aromatic C=C stretching). 
Finally, a literature search for the compound was undertaken and it was found that the 
IH and 13C NMR data of compound 5 matched that of 8-0-demethyl-7-0-methyl-
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3,9-dihydropunctatin (or 5,8-dihydroxy-3-( 4 '-hydroxybenzyl)-7 -methoxy-4-
chromanone, previously isolated from Muscari comosum.4,7 
Table 4.10: H, 13 C, HMBC, COSY and NOESY data for compound 5 (CD3OD) 
IHlppm 13C/ HMBC COSY NOESY 
ppm C-+-H 
2 a-4.30 dd, 11.4, 4.2 70.5 H-9a,b H-3 H-2b, H-3 
b-4.14 dd, 11.4, 7.1 H-2a, H-3 
3 2.83 m 48.5 H-9a,b, H-2b H-9a,b H-9a,b, H-
H-2a,b 2a,b, H-2'/6' 
4 200.1 H-9a,b, H-3, 
H-2a,b 
4a 103.2 H-6 
5-0H 11.74 s* 158.2 H-6* 
6 6.14 s 93.4 7-0CH3 7-0CH3 
7 158.0 H-6,7-0CH3 
8 127.6 H-6 
8a 149.2 H-2 
9 a-3.10 dd, 13.9,4.8 32.9 H-2a,b H-9a, H-3 H-9b, H-3, 
H-2'/6' 
b-2.66 dd, 13.9,10.4 H-9b, H-3 H-9a, H-2b, 
H-2'/6' 
l' 130.2 H-9a,b, H-3'/5' 
2'/6' 7.06 d, 8.6 131.2 H-9a,b, H-3'/5' H-3'/5' H-9a,b, H-
3, H-3'/5' 
3'/5' 6.73 d, 8.6 116.4 H-2'/6' H-2'/6' 
4' 157.2 H-3'/5', H-2'/6' 
7-0CB 3 3.87 s 56.7 H-6 
* Observed with CDCh 
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Table 4.11: Comparison of ID NMR data for compound 5 with 8-0-demethyl-7-
o h I 3 9 d·h d . 4 -met lyl- , - I ly4 ropunctatin 
ID NMR data of TD NMR data of ID NMR data from 
compound 5 compound 5 literature
4 
(CDCh)/ppm (CD30D)/ ppm (CD30D)! ppm 
2 a-4.34 dd, 11.3, 3.2 a-4.30 dd, 11.4, 4.2 a-4.29 dd, 11.4, 4.4 
b-4.19 dd, 11.3,6.6 b-4.14 dd, 11.4, 7.1 b-4.12 dd, 11.4, 7.3 
3 2.80m 2.83 m 2.82m 
5-0D 11.74 s 
6 6.12 s 6.14 s 6.12 s 
9 a-3.13 dd, 13.5,4.2 a-3.10 dd, 13.9,4.8 a-3.10 dd, 13.6,4.0 
b-2.72 dd, 13.5, 10.5 b-2.66 dd, 13.9, 10.4 b-2.64 dd, 13.6, 10.3 
2'/6' 7.08 d, 8.3 7.06 d, 8.6 7.06 d, 8.1 
3'/5' 6.78 d, 8.3 6.73 d, 8.6 6.72 d, 8.1 
7-0CD3 3.90 S 3.87 s 3.86 s 
Table 4.12: Comparison of l3C NMR data for compound 5 with 8-0-demethyl-7-
o 39 4 -methyl- , -dihydropunctatin 
BC NMR data of compound 5 l3C NMR data from literature 
(CD30D)/ ppm (CD30D) 4/ ppm 
2 70.5 70.5 
3 48.5 48.8 
4 200.1 200.1 
4a 103.2 103.2 
5 158.2 158.2 
6 93.4 93.5 
7 158.0 158.1 
8 127.6 127.6 
8a 149.2 149.2 
9 32.9 32.8 
l' 130.2 130.2 
2'/6' 131.2 131.1 
3'/5' 116.4 116.4 
4' 157.2 157.2 
7-0CD3 56.7 56.7 
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4.2.6. Structural elucidation of compound 6: 7-0-methyl-3,9-dihydropunctatin 
(spectra 6.1-6.14, pp 200-212) 
Compound 6 was isolated as a yellow amorphous solid. 
OCH3 H 
H3CO 0 OH 
2 4' 
3 
H H 9 
H 
OH 0 H 
Figure 4.7: Structure of compound 6: 7-0-methyl-3,9-dihydropunctatin 
This compound gave a molecular ion [Mj peak at mlz 330 in the mass spectrum 
[spectrum 6.13] that corresponded to a molecular formula of C1sH1s06. A double 
bond equivalence of ten was deduced. UV absorption maxima were obtained at 287 
(log E 3.18) and 229 nm (log E 3.21) [spectrum 6.10]. 
The splitting pattern for the 2H-2, H-3 and 2H-9 protons in the IH NMR spectrum 
[spectrum 6.1] was characteristic for the 3-benzyl-4-chromanone-type 
homoisoflavonoids. These were similar to compounds 2-5. 
The 1 H NMR spectrum showed the presence of two methoxy group proton resonances 
at OH 3.86 and OH 3.68 integrating to three protons each. The single proton resonance 
at OH 6.16 was assigned to the A ring. The aromatic doublet resonances at OH 7.06 (J = 
8.5 Hz) and OH 6.73 (J = 8.5 Hz) indicated ortho coupling and a para-disubstituted B 
ring. These resonances were attributed to the H-2'/6' and H-3'/5' protons respectively. 
The intense signals observed at mlz 223 and mlz 107 in the mass spectrum were due to 
the A-4 type fragmentation. The peak at mlz 223 indicated that the A-ring had one 
hydroxy and two methoxy substituents. The signal at mlz 197 was typically formed 
via the RDA and hydrogen-shift of the chromanone fragment. The hydroxytropylium 
ion at mlz 107 indicated a single hydroxy group on the B-ring and this was assigned to 
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Scheme 4.5: Mass spectral fragmentation pattern for compound 6 
UV spectra were used to assign the substituents on the A ring. A bathochromic shift 
(+25 run) was observed with AICh [spectrum 6.11] and this indicated the presence of 
a hydroxy group at the C-5 position.6 This strongly hydrogen-bonded 5-hydroxy 
group proton resonance was observed at OH 12.03 in the IH NMR spectrum [spectrum 
6.2] run in deuterated chloroform. This was confirmed by the downfield resonance of 
C-4 at Oc 200.0 in the l3C NMR spectrum [spectrum 6.3]. No bathochromic shift was 
observed with NaOAc [spectrum 6.12] and this indicated a methoxy group at the C-7 
position.6 The singlet proton resonance in the IH NMR spectrum occurred downfield 
of OH 6.00 and this confirmed the absence of a hydroxy group at C_7.4 
A NOESY correlation between the 5-0H proton and the singlet resonance at OH 6.09 
was observed in the NOESY spectrum [spectrum 6.9] run in deuterated chloroform. 
This resonance was therefore assigned to H-6. The methoxy group proton resonance 
at OH 3.86 was placed at the C-7 position because it showed a NOESY correlation 
[spectrum 6.8] to the H-6 proton. The second methoxy group at OH 3.68 was then 
placed at the remaining C-8 position. 
Placement of the methoxy group at the C-8 position was confirmed by comparison of 
the l3C NMR data with the literature values of 7-0-methyl-3,9-dihydropunctatin and 
7-0-methyl-3,9-dihydroeucomnalin (Table 4.15).4 It was found that placement of the 
methoxy group at the C-6 or C-8 position has an effect on the chemical shift of the C-
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5, C-6, C-8 and the C-8a resonances. As shown in Table 4.15, the resonances of 
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Figure 4.8: Structure of 7-O-methyl-3,9-
dihydropuDctatin 
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The IR spectrum [spectrum 6.14] further supported the proposed structure. Peaks 
were observed at 3414 cm-1 (O-H stretching), 2932 cm-1 (aliphatic C-H stretching), 
1641 cm-1 (C=O stretching) and 1520 cm-1 (aromatic C=C stretching). 
Compound 6 was found to be the known compound 7-0-methyl-3,9-dihydro-
punctatin (or 5-hydroxy-3-( 4 '-hydroxybenzyl)-7 ,8-dimethoxy-4-chromanone). 
This compound has been previously isolated from Muscari comosum and Ledebouria 
coo peri. 4, 10 
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Table 4.13: H, 13 C, HMBC, COSY and NOESY data for compound 6 (CD3OD) 
IH/ppm 13C/ HMBC NOESY COSY 
ppm C~H 
2 a-4.16 dd, 11.4, 70.6 H-9a,b H-2b, H-3 H-3 
7.1 
b-4.32 dd, 11.4, H-2a, H-3 
4.4 
3 2.85m 48.2 H-9a,b, H-2a H-2b, H-9a,b, H-9a,b, H-2a 
H-2'/6' 
4 200.0 H-2a,b, H-
9a,b 
4a 103.2 H-6 
5-0H 12.03 s* 161.5 H-6 H-6* 
6 6.16 s 93.8 7-0CH3 
7 162.7 7-0CH3 H-6 
8 130.4 8-0CH3, H-6 
8a 155.1 H-2a,b 
9 a-2.67 dd, 13.9, 33.0 H-2a,b, H- H-9b, H-2'/6' H-3, H-9b 
10.1 2'/6' 
b-3.10 dd, 13.9, H-9a, H-3, H-9a 
4.2 H-2'/6' 
l' 129.9 H-9a,b, H-
3'/5' 
2'/6' 7.06 d, 8.5 131.2 H-2a,b, H-3, H-3'/5' 
H-3'/5' 
3'/5' 6.73 d, 8.5 116.4 H-9a,b H-2'/6' H-2'/6' 
4' 157.3 H-2'/6', H-
3'/5' 
7-0CH3 3.86 56.7 8-0CH3 H-6 
8-0CH3 3.68 s 61.5 7-0CH3 
*Observed with CDCI3 
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Table 4.14: Comparison of IH NMR data for compound 6 with 7-0-methyl-3,9-
dOh d 0 4 I lY4 ropunctatm 
IH NMR data of IH NMR data of IH NMR data from 
compound 6 compound 6 literature 
(CDCh)/ppm (CD30D)! ppm (CD30D)4/ ppm 
2 a-4.18 dd, 11.4, 6.9 a-4.16dd, 11.4,7.1 a-4.12 dd, 11.4, 7.3 
b-4.33 dd, 11.4, 4.2 b-4.32 dd, 11.4,4.4 b-4.29 dd, 11.4,4.4 
3 2.80m 2.85m 2.83m 
5-0H 12.03 s 
6 6.09 s 6.16 s 6.11 s 
9 a-2.70 dd, 13.7, 10.4 a-2.67 dd, 13.9, 10.1 a-2.61 dd 13.6,9.6 
b-3.14 dd, 13.7,4.4 b-3.10 dd, 13.9,4.2 b-3.08 dd, 13.6,4.0 
2'/6' 7.08 d, 8.5 7.06 d, 8.5 7.03 d, 8.5 
3'/5' 6.77 d, 8.5 6.73 d, 8.5 6.72 d, 8.5 
7-0CH3 3.87 S 3.86 s 3.84 s 
8-0CH3 3.76 S 3.68 s 3.66 s 
Table 4.15: Comparison of 13C NMR data for compound 6 with 7-0-methyl-3,9-
oliO 3 4 dlhydroeucomna nand 7- -methyl- ,9-dihydropunctatin 
13C data of 13C data of 3,9- 13C data of 3,9-
compound 6 dihydroeucomnalin dihydropunctatin 
(CD30D)/ ppm (CD30D)4/ ppm (CD30D)4/ ppm 
2 70.6 70.6 70.4 
3 48.2 48.1 48.8 
4 200.0 200.5 199.8 
4a 103.2 103.7 103.3 
5 161.5 156.2 161.3 
6 93.8 131.4 93.8 
7 162.7 162.3 162.5 
8 130.4 92.6 130.3 
8a 155.1 160.6 154.9 
9 33.0 32.9 32.0 
l' 129.9 130.1 129.7 
2'/6' 131.2 131.2 131.0 
3'/5' 116.4 116.5 116.4 
4' 157.3 157.3 157.2 
6-0CH3 61.1 
7-0CH3 56.7 56.7 56.7 
8-0CH3 61.5 61.5 
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4.2.7. Structural elucidation of compound 7: 7-bydroxy-3-(4'-bydroxybenzyl)-
5,6-dimetboxy-4-cbromanone (spectra 7.1-7.13, pp 213-224) 
This compound was isolated as a yellow amorphous substance. 
H H 
HO H OH 
9 H 
H 
Figure 4.10: Structure of compound 7: S,6-dimethoxy-7 -hydroxy-3-( 4' -hydroxybenzyl)-4-
chromanone 
Compound 7 gave a molecular ion [Ml peak at m/z 330 in the mass spectrum 
[spectrum 7.12]. This corresponded to a molecular formula of ClsHlS06 from which 
a double bond equivalence of ten was deduced. UV absorption maxima were obtained 
at 321 (log E 3.53), 277 nm (log E 3.87) and 232 nm (log E 4.56) [spectrum 7.9]. 
The distinctive 2H-2, H-3 and 2H-9 resonances for 3-benzyl-4-chromanone type 
homoisoflavonoids were evident in the aliphatic region of the IH NMR spectrum 
[spectrum 7.1] for this compound. 
The fragmentation pattern for this compound was the same as compound 6. A 
hydroxydimethoxy fragment at m/z 223 in. the mass spectrum indicated the 
substituents on the A ring whereas the hydroxytropylium fragment at m/z 107 
indicated a hydroxylated B ring. The aromatic resonances at DH 7.06 (d, J = 8.4 Hz) 
and DH 6.76 (d, J = 8.4 Hz) assigned to H-2'/6' and H-3'/5' indicated a para-
disubstituted B ring. A hydroxy group was assigned to the C-4' position. 
The IH NMR and UV spectra confirmed substituents on the A ring that were indicated 
by the mass spectrum. The singlet at DH 6.29 was assigned to H-8 because of the 
HMBC correlation with C-8a. The presence of a singlet proton resonance indicated 
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only one unsubstituted position on the A ring. Two overlapped singlets integrated to 
six protons at DH 3.89 indicated that two methoxy groups were present. One methoxy 
group was placed at the C-5 position because no bathochromic shift was observed 
with AICb in the UV spectrum [spectrum 7.10].6 The appearance of a carbonyl group 
at Dc 191.9 in the \3C NMR spectrum [spectrum 7.2] further supported the placement 
of the methoxy group at the C-5 position. If a hydroxy group was present at C-5, the 
C-4 resonance would have resonated further downfield as in compound 6. A hydroxy 
group was placed at the C-7 position because a bathochromic shift (+43 nm) was 
observed with NaOAc [spectrum 7.11].6 The other methoxy group was then placed at 
the remaining C-6 position. One methoxy group showed an HMBC correlation to the 
C-5 resonance at Dc 153.6 and the other to the C-6 resonance at Dc 135.2 and this 
confirmed placement of the methoxy groups at the C-5 and C-6 positions. 
H H H 
OH HO OH 
H 
H3CO H 
OH H OCH3 O H 
compound 6 compound 7 
Figure 4.11: Comparison of structures of compound 6 and compound 7 
The IR spectrum [spectrum 7.13] further supported the postulated structure of the 
homoisoflavonoid. Peaks were observed at 3368 cm-1 (O-H stretching), 2921 cm-1 
(aliphatic C-H stretching), 1618 cm-1 (C=O stretching) and 1525 cm-1 (aromatic C=C 
stretching). 
The \3C NMR data of compound 7 was compared to the literature values of 7-0-
methyl-3,9-dihydropunctatin and 7-0-methyl-3,9-dihydroeucomnalin (Table 4.17) 
and it was found that the values did not match either of the compounds.4 Compound 7 
was found to be the novel compound 7-hydroxy-3-(4'-hydroxybenzyl)-S,6-
dimethoxy-4-chromanone. 
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Table 4.16: H, 13 C, HMBC, COSY and NOESY data for compound 7 (CDCh) 
IH/ppm 13C/ppm HMBC NOESY COSY 
C--+H 
2 a-4.06 dd, 68.8 H-9b, H-3 H-9b, H-3 H-2b 
11.4,6.8 
b-4.23 dd, H-9b H-2a 
11.4,3.8 
3 2.68m 48.5 H-9a,b H-9a,2a H-9a, H-2a,b 
4 191.9 H-2a,b, H-8 
4a 108.6 H-8 
5 153.6 5-0CH3 
6 135.2 6-0CH3, H-8 
7 155.7 H-8 
8 6.29 s 98.9 
8a 159.8 H-2a,b, H-8 
9 a-2.63 dd, 32.0 H-2a,b, H- H-9b, H-3, H-9b, H-3 
12.8, 10.4 2'/6' H-2'/6' 
b-3.12 dd, H-9a, H-2b, H-9a, 
12.8,3.7 H-2'/6' 
l' 130.1 H-3, H-9a,b, 
H-2'/6', H-
3'/5' 
2'/6' 7.06 d, 8.4 130.2 H-9a,b, H- H-9a,b, H-3, H-3'/5' 
3'/5' H-2b, H-
3'/5' 
3'/5' 6.76 d, 8.4 115.5 H-2'/6' H-2'/6' H-2'/6' 
4' 154.5 H-2'/6', H-
3'/5' 
5-0CH3 3.89 S 61.4 
6-0CH3 3.89 S 61.5 
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Table 4.17: Comparison of 13C NMR data for compound 7 with 7-0-methyl-3,9-
dOh d Ii d 70th I 3 9 dOh d t f 4 I ly4 roeucomna n an - -me lyJ - , - lly4 ropunc a ID 
l3C data of TIC data of l3C data of 3,9- 13C data of 3,9-
compound compound 7 dihydroeucomnaIin dihydropunctatin 
7 (CDCh)1 (CD30D)1 (CD30Dtl ppm (CD30Dtl ppm 
ppm ppm 
2 68.8 70.0 70.6 70.4 
3 48.5 50.1 48.1 48.8 
4 191.9 194.0 200.5 199.8 
4a 108.6 108.9 103.7 103.3 
5 153.6 155.9 156.2 161.3 
6 135.2 137.7 131.4 93.8 
7 155.7 159.6 162.3 162.5 
8 98.9 100.5 92.6 130.3 
8a 159.8 161.4 160.6 154.9 
9 32.0 33.2 32.9 32.0 
l' 130.1 130.4 130.1 129.7 
2'/6' 130.2 131.2 131.2 131.0 
3'/5' 115.5 116.4 116.5 116.4 
4' 154.5 157.1 157.3 157.2 
5-0CH3 61.4 61.9 
6-0CH3 61.5 61.6 61.1 
7-0CH3 56.7 56.7 
8-0CH3 61.5 
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4.2.8. Structural elucidation of compound 8: 3,5,7-tribydroxy-3-(4'-bydroxy-
benzyl)-4-cbromanone (spectra 8.l-8.l2, pp 225-235) 










Figure 4.12: Structure of compound 8: 3,S,7-trihydroxy-3-(4'-hydroxybenzyl)-4-chromanone 
The mass spectrum [spectrum 8.11] gave a molecular ion [Ml peak at mlz 302. This 
corresponded to a molecular formula of C16H1406 from which a double bond 
equivalence of ten was deduced. UV absorption maxima were obtained at 291 nm (log 
E 3.69) [spectrum 8.8]. 
Compound 8 was similar to compound 2 but differed in that it had a hydroxy group at 
C-3 rather than a hydrogen atom as in compound 2. This was indicated by the lack of 
the H-3 resonance in the IH NMR spectrum [spectrum 8.1]. The 13C NMR spectrum 
[spectrum 8.3] indicated an extra C-O signal at 8e 73.5 and this indicated that a 
hydroxy group was present at C-3. 
H H H H 
OH HO OH 
H 
H 
OH H OH H 
compound 2 compound 8 
Figure 4.13: Comparison of structures of compound 2 and compound 8 
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The IH NMR spectrum showed aliphatic resonances that were definitive for 3-benzyl-
3-hydroxy-4-chromanone type homoisoflavonoids. The doublet resonances at OH 3.94 
(J = 11.3 Hz) and OH 4.04 (J = 11.3 Hz) were attributed to the two non-equivalent H-2 
protons. The resonance at OH 2.88 was attributed to the two non-equivalent 2H-9 
protons. This resonance was typical of a non-first-order resonance. In general, first-
order resonances only arise if the chemical shift difference between signals is much 
larger than the coupling constant. However, if signals from the coupling protons are 
closer together in the spectrum, and the chemical shift difference is small, distortion 
of the signals arise. As a result, the signals move together, the inner peaks become 
even larger at the expense of the outer peaks, and the position of the lines also change: 
the original chemical shift positions are no longer found at the midpoints of the 
doublets, but lie approximately at the 'center of gravity' of the doublets. ll 
The substitution pattern on the A and B rings were the same as in compound 2 and 
this was indicated by the IH NMR, mass and UV spectra. The IH NMR spectrum 
showed the meta-coupled protons: H-6 at OH 5.91 (d, J = 2.1 Hz) and H-8 at OH 5.89 
(d, J = 2.1 Hz) of the A-ring. Hydroxy groups were placed at the C-5 and C-7 
positions because bathochromic shifts were observed with AICh (+16 nm) and 
NaOAc (+37 nm) in the UV spectrum [spectra 8.9 and 8.10].6 Placement of the 
hydroxy group at the C-5 position was confirmed by the downfield C-4 resonance at 
Oc 200.0 while placement of the hydroxy at the C-7 position was confirmed by the 
appearance of the C-6 resonance at Oc 97.4 and the C-8 resonance at Oc 96.1.4 
The mass spectrum showed peaks at mlz 195 and mlz 107 that resulted from an A-4 
type fragmentation pattern. The peak at mlz 195 indicated that the chromanone 
fragment contained three hydroxy groups. A RDA and hydrogen-shift of the 
chromanone fragment resulted in the peak at mlz 153. This ion was primary evidence 
for a C-3 hydroxy substituent. If a third hydroxy substituent of the chromone fragment 
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Scheme 4.6: Mass spectral fragmentation pattern for compound 8 
A para-disubstituted B-ring was indicated from the H-2'/6' resonance at <>H 7.05 (d, J 
= 8.5 Hz) and the H-3'/5' resonance at <>H 6.70 (d, J = 8.5 Hz). The resonance at <>e 
157.5 showed HMBC correlations to the H-2'/6' and H-3'/5' protons in the HMBC 
spectrum [spectrum 8.5] and was assigned to C-4'. The mass spectrum indicated a 
hydroxytropylium peak at mlz 107 therefore a hydroxy group was placed at the C-4' 
position since the B ring was para-disubstituted. 
The IR data [spectrum 8.12] obtained for this compound was consistent with the 
proposed structure. Peaks were observed at 3337 cm- l (O-H stretching), 2915 cm- l 
(aliphatic C-H stretching), 1646 cm- l (C=O stretching) and 1521 cm- l (aromatic C=C 
stretching). 
Finally, a literature search for compound 8 revealed that it was 3,5,7-trihydroxy-3-
(4'-hydroxybenzyl)-4-chromanone.6 Compound 8 gave an optical rotation of +710 
and differs from that isolated from Eucomis bicolor found in literature which gave an 
optical rotation of -900 and for which the hydroxy group at C-3 was shown as a.6 A 
thorough literature search was then undertaken to determine how these researchers 
had proven the absolute stereochemistry. The literature reference referred to a PhD 
thesis by W. Schaad (1976) so an attempt was made to search the Chemical Abstracts 
to locate related pUblications. The publication found based on his PhD work, did not 
explain how the absolute stereochemistry had been determined.8 On the basis of this 
lack of evidence relating to the assignment of the absolute stereochemistry at C-3 of 
3,5,7-trihydroxy-3-(4'-hydroxybenzyl)-4-chromanone in the paper referenced8, the 
absolute stereochemistry would is in doubt. The absolute configuration of a 
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compound can only be proven by using the technique of circular dichroism and no 
mention is made of this in the publication. Thus from the optical rotations it would 
seem as though the compounds isolated from the two sources, Eueomis montana and 
Eueomis hieolor, have opposite stereochemistry at C-3. However, Eueomis montana 
and Eueomis hieolor belong to the same genus and one would have expected them to 
have the same absolute configuration at C-3. 
Table 4.18: H, 13 C, HMBC, NOESY and COSY data for compound 8 (CD30D) 
IHJppm 13C /ppm HMBC NOESY COSY 
C-H 
2 a-3.94 d, 11.3 72.3 H-9 H-2b 
b-4.04 d, 11.3 H-2'/6', H-2a 
3 73.5 H-9, H-2a,b 
4 200.0 H-9, H-2a,b 
4a 101.4 H-6, H-8 
5 165.8 H-6 
6 5.91 d,2.1 97.4 H-8 H-8 
7 168.6 H-8 
8 5.89 d, 2.1 96.1 H-6 H-6 
8a 164.4 H-2a,b, H-8 
9 2.88* 40.7 H-2a,b, H-2'/6' H-2'/6' 
l' 126.9 H-9, H-3'/5' 
2'/6' 7.05 d, 8.5 132.8 H-9 H-9, H-3'/5' H-3'/5' 
3'/5' 6.70 d, 8.5 115.9 H-2'/6' H-2'/6' 
4' 157.5 H-2'/6', H-3'/5' 
* The two H-9 proton resonances are supenmposed in the IH NMR spectrum (non-first order 
resonances) 
Table 4.19: IH NMR data for compound 8 and 3,5,7-trihydroxy-3-(4'-
6 hydroxybenzyl)-4-chromanone 
IHNMRdata IH NMR data for IH NMR data for 3,5,7-
for compound 8 compound 8 trihydroxy-3-( 4'-
(CD30D)/ ppm {(CD3)2CO)/ ppm hydroxybenzyl)-4-chromanone 
((CD3)2CO)6/ ppm 
2 a-3.94 d, 11.3 a-4.05 d, 11.3 a-4.04 d, 11.3 
b-4.04 d, 11.3 b-4.13 d, 11.3 b-4.11 d, 11.3 
6 5.91 d,2.1 6.01 d,2.2 5.99 d, 2.3 
8 5.89 d, 2.1 6.00 d, 2.2 5.97 d, 2.3 
9 2.88* 2.94* 2.93 s 
2'/6' 7.05 d, 8.5 7.14 d, 8.5 7.12 d, 8.8 
3'/5' 6.70 d, 8.5 6.79 d, 8.5 6.77 d, 8.8 
5-0H 11.79 s 11.75 s 
* The two H-9 protons resonances are supenmposed in the IH NMR spectrum (non-first order 
resonances) 
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4.2.9. Structural elucidation of compound 9: eucomol (spectra 9.1-9.12, pp 236-
246) 








OH 0 OH H 
Figure 4.14: Structure of compound 9: eucomol 
The mass spectrum [spectrum 9.11] gave a low intensity molecular ion [Mi peak at 
mlz 316 that corresponded to a molecular fonnula of C17HI606. From this a double 
bond equivalence of ten was deduced. UV absorption maxima [spectrum 9.8] were 
obtained at 293 nm (log E 4.15) and 235 nm (log E 4.59). 
The splitting pattern shown in the IH NMR spectrum [spectrum 9.1] for the 2H-2 and 
2H-9 protons were typical of 3-benzyl-3-hydroxy-4-chromanone type 
homoisoflavonoids. The doublet resonances at OH 4.17 (J = 11.1 Hz) and OH 4.03 (J = 
11.1 Hz) assigned to 2H-2 and the resonance at OH 2.93 assigned to 2H-9 were similar 
to those of compound 8. Furthennore an oxygenated C-3 resonance was indicated 
from the appearance of a peak at Oc 72.2 in the I3C NMR spectrum [spectrum 9.2] 
that showed HMBC correlations to the 2H-2 and 2H-9 proton resonances in the 
HMBC spectrum [spectrum 9.5]. 
The IH NMR, UV and mass spectra showed that the substitution pattern of the A and 
B rings were the same as in compound 3. The pair of doublet resonances at OH 6.02 (J 
= 2.2 Hz) and OH 5.97 (J = 2.2 Hz) in the IH NMR spectrum were assigned to H-6 and 
H-8 respectively and this indicated substituents at C-5 and C-7 on the A ring. The UV 
spectra [spectra 9.9 and 9.10] showed bathochromic shifts with AICh (+15 nm) and 
NaOAc (+34 nm) and this allowed placement of hydroxy groups at the C-5 and C-7 
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positions.6 The C-4 carbonyl resonance observed at Dc 198.1 in the 13C NMR 
spectrum confinned the hydroxy group at the C-5 position whereas the C-6 resonance 
at Dc 97.1 and the C-8 resonance at Dc 95.8 confinned the hydroxy group at the C-7 
position.4 
H H H H 
0 OCH3 OCH3 
H H 
OH 0 H OH 0 H 
compound 3 compound 9 
Figure 4.15: Comparison of structures of compound 3 and compound 9 
The A-4 fragmentation pattern produced peaks at mlz 195, 153 and 121 as shown in 
the mass spectrum. The peak at mlz 153 was due to a RDA and hydrogen-shift of the 
chromanone fragment and indicated that the A ring contained two hydroxy groups. 
The A-4 fragmentation ion at mlz 195 indicated that the third hydroxy group belonged 
to C-3 of the chromanone fragment. The methoxytropylium ion at mlz 121 indicated 
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Scheme 4.7: Mass spectral fragmentation pattern for compound 9 
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A para-disubstituted B ring was indicated by the pair of doublets integrating to two 
protons each at OH 7.10 (J= 8.8 Hz) and OH 6.83 (J= 8.8 Hz) assigned to H-2'/6' and 
H-3'/5' respectively. The methoxy group resonance at OH 3.77 showed a positive 
NOESY correlation [spectrum 9.7] to the H-3'/5' doublet resonance and was thus 
assigned to the C-4' position. 
The IR spectrum [spectrum 9.12] showed peaks that agreed with the proposed 
structure of compound 9. The peak at 3408 cm-I indicated O-H stretching and the 
peak at 1638 cm-I indicated C=O stretching. Peaks were also observed for aliphatic C-
H stretching at 2922 cm-I and for the aromatic C=C stretching at 1513 cm-I. 
Finally, a literature search for compound 9 was undertaken and it was found that the 
IH NMR data (Table 4.21) matched that of the known compound eucomol (or 3,5,7-
trihydroxy-3-(4'-methoxybenzyl)-4-chromanone}, previously isolated from 
Eueomis hieolor and Scilla draeomontana.8,12 
Table 4.20: H, 13 C, HMBC, NOESY and COSY data for compound 9 (CDCI 
IH/ppm JJC IIMBC COSY NOESY 
/ppm C-H 
2 a-4.17 d, 11.1 71.7 2H-9 H-2b H-2b,2H-9, 
H-2'/6' 
b-4.03 d, 11.1 2H-9 H-2a 
3 72.2 H-2a,b, 2H-9 
4 198.1 2H-9, H-2a,b 
4a 100.4 H-8, H-6 
5 11.28 s 164.1 H-6 
6 6.02 d, 2.2 97.1 H-8 
7 165.8 H-8, H-6 
8 5.97 d, 2.2 95.8 H-6 
8a 163.0 H-2a,b, H-8 
9 2.93* 40.6 H-2a,b, H-2'/6' H-2b H-2'/6' 
l' 126.0 H-3'/5', 2H-9 
2'/6' 7.10 d, 8.8 131.6 H-3'/5', 2H-9 H-3'/5' 2H-9, H-2a, 
H-3'/5' 
3'/5' 6.83 d, 8.8 113.8 H-2'/6' H-2'/6' H-2'/6', 4'-
OCH3 
4' 158.7 H-3'/5', H-2'/6' 
4'- 3.77 s 55.3 H-3 '/5 , 
OCH3 
* The two H-9 proton resonances are superImposed ID the 1H NMR spectrum (non-first order 
resonances) 
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T bI 421 C d9 d a e . omparlson 0 aa or compoun an eucomo . . 
IH NMR data of compound 9 IH NMR data from literature 
(CDCh)lppm 1CDCI~6,8/ J!I!m 
2 a-4.17 d, 11.1 a-4.21 d, 11.2 
b-4.03 d, 11.1 b-4.06 d, 11.2 
5-0H 11.28 bs 11.26 s 
6 6.02 d, 2.2 6.03 d,2.3 
8 5.97 d, 2.2 5.99 d, 2.3 
9 2.93* 2.95 s 
2'/6' 7.10 d, 8.8 7.11 d, 8.8 
3'/5' 6.83 d, 8.8 6.87 d, 8.8 
4'- 3.77 s 3.80 s 
OCH3 
* The two H-9 proton resonances are supenmposed ID the IH NMR spectrum (non-first order 
resonances) 
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4.2.10. Structural elucidation of compound 10: 7-0-methyleucomol (spectra 10-
10.12, pp 247-258) 




OH 0 H 
Figure 4.16: Structure of compound 10: 7-0-methyleucomol 
The mass spectrum [spectrum 10.11] gave a low intensity molecular ion [M+] peak at 
mlz 330. This corresponded to a molecular formula of C1sH1s06 from which a double 
bond equivalence of ten was deduced. UV absorption maxima were obtained at 293 
nm (log E 3.42) and 232 nm (log E 3.50) [spectrum 10.8]. 
The IH NMR spectrum [spectrum 10.1] showed resonances in the aliphatic region 
that were typical of 3-benzyl-3-hydroxy-4-chromanone type homoisoflavonoids. 
These were the doublet resonances at OH 4.04 (J = 11.2 Hz) and OH 4.19 (J = 11.2 Hz) 
attributed to 2H-2 and the resonance at OH 2.93, integrating to two protons, attributed 
to 2H-9. 
The meta-coupled protons H-6 and H-8 were indicated from the pair of doublets at OH 
6.10 (J = 2.2 Hz) and OH 6.03 (J = 2.2 Hz) integrating to one proton each in the IH 
NMR spectrum. The HMBC correlation [spectrum 10.5] observed between the C-8a 
resonance and the doublet at OH 6.03 allowed assignment of H-8. The remaining 
doublet was then assigned to H-6. The two substituents that were assigned to the C-5 
and C-7 position were determined with the aid of the UV and mass spectrum. The UV 
spectrum [spectrum 10.9] showed a bathochromic shift of +18 nm with AICh. This 
indicated that a hydroxy group was present at the C-5 position.6 The C-4 carbonyl 
resonance was observed at Oc 198.3 in the I3C NMR spectrum [spectrum 10.2] and 
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this confirmed placement of the C-5 hydroxy group. No shift was observed with 
NaOAc. The methoxy group proton resonance at OH 3.82 was placed in the C-7 
position as this resonance showed NOESY correlations [spectrum 10.7] to the H-6 
and H-8 resonances. Both the A ring doublet resonances were deshielded (>6.00 ppm) 
which further supported this assignment of the methoxy group at the C-7 position.4 
A para-dibsubstituted B ring was indicated from the pair of doublet resonances at OH 
7.10 (J = 8.6 Hz) and OH 6.83 (J = 8.6 Hz) assigned to H-2'/6' and H-3'/5' respectively. 
The methoxy group proton resonance at OH 3.78 was placed at the C-4' position 
because it showed a positive NOESY correlation to the H-3'/5' protons. 
The mass spectrum confirmed the substitution pattern on the A and B rings. The A-4 
fragmentation pattern resulted in fragment ions at m/z 209 and m/z 121. The peak at 
m/z 209 indicated the presence of two hydroxy groups and one methoxy group on the 
chromanone fragment. The chromanone fragment upon a RDA and hydrogen-shift 
resulted in the peak at m/z 167 which confirmed the placement of the hydroxy and 
methoxy substituents on the A ring and the C-3 hydroxy substituent. The 
methoxytropylium ion, indicated by the fragment ion at m/z 121, confirmed the 
substitution pattern on the B ring (Scheme 4.8). 
OH 0 OH 
mlz 330 






Scheme 4.8: Mass spectral fragmentation pattern for compound 10 
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The IR spectrum [spectrum 10.12] further supported the proposed structure. Peaks 
were observed at 3381 cm-1 (O-H stretching), 2921 cm-1 (aliphatic C-H stretching), 
1651 cm-1 (C=O stretching) and 1512 cm-1 (aromatic C=C stretching). 
Finally, a literature search for compound 10 was undertaken and it was found that the 
IH NMR data matched that of the known compound, 7-0-methyleucomol (or 3,5-
dihydroxy-7 -methoxy-3-( 4 '-methoxybenzyl)-4-chromanone) that has been isolated 
previously from Eueomis bieolor and Ornithogalum longibraeteatum.8,13 
Table 4.22: H, 13 C, HMBC, NOESY and COSY data for compound 10 (CDCh) 
IHlppm 13C/ HMBC NOESY COSY 
ppm C-+H 
2 a-4.04 d, 71.8 2H-9 H-2b H-2b 
11.2 
b-4.19 d, H-2a, 2H-9,H- H-2a 
11.2 2'/6' 
3 72.2 H-2a,b 
4 198.3 H-2a,b, 2H-9 
4a 100.5 H-6, H-8 
5-0H 11.23 s 164.0 H-6 
6 6.10 d, 2.2 95.4 H-8 7-0CH3 
7 168.6 H-6, H-8, 7-
OCH3 
S 6.03 d, 2.2 94.5 H-6 7-0CH3 
Sa 162.7 H-2b, H-8 
9 2.93· 40.7 H-2'/6', H-2a,b H-2'/6', H-2b 
l' 126.1 H-3'/5', 2H-9 
2'/6' 7.10 d, 8.6 131.5 H-3'/5', 2H-9 2H-9, H-2b, H- H-3'/5' 
3'/5' 
3'/5' 6.83 d, 8.6 113.7 H-2'/6' 4'-OCH3, H-2'/6' H-2'/6' 
4' 158.8 4'-OCH3, H-2'/6', 
H-3'/5' 
4'-OCH3 3.78 s 55.2 H-3'/5' H-3'/5' 
7-0CH3 3.82 s 55.8 H-6, H-8 
* The 2H-9 proton resonances are superimposed ID the IH NMR spectrum (non-first order 
resonances) 
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Table 4.23: Comparison of IH NMR data for compound 10 with 7-0-methyl-
eucomol s 
IH NMR of compound 10 IH NMR data from literature 
(CDCh)/ppm (CDCh)8/ ppm 
2 4.04 d, 11.2 4.06 d, 11.2 
4.19 d, 11.2 4.21 d, 11.2 
5-0H 11.23 s 11.24 s 
6 6.10 d, 2.2 6.12 d, 2.3 
8 6.03 d, 2.2 6.05 d, 2.3 
9 2.93 * 2.95 s 
2'/6' 7.10 d, 8.6 7.12 d, 8.8 
3'/5' 6.83 d, 8.6 6.85 d, 8.8 
4'-OCH3 3.78 S 3.80 s 
7-0CH3 3.82 S 3.85 s 
* The 2H-9 proton resonances are superimposed in the IH NMR spectrum (non-first order 
resonances) 
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4.2.11. Structural elucidation of compound 11: (E)-eucomin (spectra 11.1-11.13, 
pp 259-270) 













Figure 4.17: Structure of compound 11: (E)-eucomin 
The mass spectrum [spectrum 11.12] gave a molecular ion [M+] peak at mlz 298. 
This corresponded to a molecular formula of C17HI40 S from which a double bond 
equivalence of eleven was deduced. UV absorption maxima were obtained at 357 nm 
(log € 3.44) and 232 nm (log € 4.27) [spectrum 11.9]. 
The IH NMR spectrum [spectrum 11.1] for compound 11 showed resonances that 
were typical of a 3-benzylidenyl-4-chromanone type homoisoflavonoid. This was 
indicated from the doublet resonance at OH 5.34 (J = 1.7 Hz) attributed to 2H-2 and 
the broad singlet at OH 7.77 attributed to the H-9 resonance. Furthermore a 
characteristic quaternary carbon resonance in the double bond region for C-3 at Oc 
128.8 as well as a resonance corresponding to a a,p-unsaturated carbonyl group 
carbon at OH 186.3 was evident in the 13C NMR spectrum [spectrum 11.3]. The 
upfield C-4 carbonyl group resonance is due to the conjugative effect of the 3,9-
double bond.6 
Substitution on the A and B rings was the same as compound 3. T!J.e IH NMR 
spectrum showed a pair of doublets at OH 5.96 (J = 2.2 Hz) and OH 5.90 (J = 2.2 Hz) 
attributed to the H-6 and H-8 protons. The UV spectrum [spectra 11.10 and 11.11] 
indicated hydroxy groups at the C-5 and C-7 positions because bathochromic shifts 
were observed with AICh (+39 nm) and NaOAc (+20 nm).6 The mass spectrum 
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showed a peak at m/z 153 due to a RDA cleavage and H-shift and this confirmed the 
two hydroxy groups on the A ring. 
H H 
HO 0 OCH3 
:::::,.... 
H H 









H H OH 
mlz 153 mlz 146 
Scheme 4.9: Mass spectral fragmentation pattern for compound 11' 
A para-disubstituted B ring was indicated from the doublet resonances at OH 7.36 (J = 
8.8 Hz) and OH 7.06 (J = 8.8 Hz) attributed to the H-2'/6' and H-3'/S' protons 
respectively. The fragment ion at m/z 146 indicated that the methoxy group was on 
the B ring, where it was placed on the C-4' position because it showed a NOESY 
correlation [spectrum 11.8] to the H-3'/S' protons. 
To determine the configuration of the 3,9-double bond, molecular models were 
constructed for both geometric isomers (E and Z). The model for the (E)-isomer 
showed that only the H-2'/6' protons were close to H-9 and therefore positive NOESY 
correlations should be observed for these protons in the NOESY spectrum. The model 
for the (Z)-isomer showed that the H-9 proton was close to the 2H-2 and H-2'/6' 
protons and therefore positive NOESY correlations should be obtained for these 
protons. 
A positive NOESY correlation was seen for the H-9 proton with the H-2'/6' protons 
only and this suggested the 3,9-double bond being in the (E)-configuration. Also, the 
2H-2 protons showed a correlation to the H-2'/6' protons only and the H-2'/6' protons 
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showed positive NOESY correlations to the 2H-2, H-9 and the H-3'/5' protons. This 
provided evidence that the geometry was indeed (E) as these results would not be 
expected for the (Z)-configuration. NOESY correlations of H-2'/6' to the mentioned 
protons can be attributed to free rotation across the C-9, C-1' bond. Further support of 
the (E)-configuration was the H-9 proton at OH 7.77 due to the presence of this 
resonance in the anisotropic region of the carbonyl groUp.6 
(E)-isomer 
Figure 4.18: Diagram showing NOESY 
correlations for the (E)-isomer 
HO 
Figure 4.19: Diagram showing NOESY 
correlations for the (Z)-isomer 
The IR data [spectrum 11.13] obtained for compound 11 supported the proposed 
structure. Peaks were observed at 3374 cm-\ (O-H stretching), 2926 cm-\ (aliphatic C-
H stretching), 1646 cm-\ (C=O stretching) and 1515 cm-\ (aromatic C=C stretching). 
Finally, a literature search for compound 11 showed that the \H and l3C NMR data 
(Tables 4.25 and 4.26) matched those of the known compound (E)-eucomin (or (E)-
5,7 -dihydroxy-3-( 4' -methoxybenzylidenyl)-4-chromanone), isolated previously 
from Eueomis bie%r.6•8 
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Table 4.24: IH, 13C, HMBC, COSy and NOESY data for compound 11 (CD3OD) 
IH/ppm J~C/ HMBC COSY NOESY 
ppm C-H 
2 5.34 d, 1.7 68.4 H-9 H-2'/6' 
3 128.8 2H-2 
4 186.3 2H-2, H-9 
4a 103.8 H-6, H-8 
5 165.9 
6 5.96 d, 2.2 97.4 H-8 
7 168.2 H-8 
8 5.90 d, 2.2 96.1 H-6 
8a 163.7 2H-2, H-8 
9 7.77 bs 137.8 2H-2, H-2'/6' 2H-2 H-2'/6' 
l' 127.8 H-3'/5' 
2'/6' 7.36 d, 8.8 133.2 H-9 H-3'/5' 2H-2, H-3'/5', H-9 
3'/5' 7.06 d, 8.8 115.3 H-2'/6' H-2'/6',4'-OCH3 
4' 162.3 4'-OCH3, H-3'/5', 
H-2'/6' 
4'- 3.89 s 56.0 H-3 '/5 , 
OCH3 
T bl 425 C a e . : ompanson 0 ata or compoun d11 ·hhli WIt t e 68 terature' 
IHNMRdata IHNMRdata IH NMR data of IH NMR data 
of compound of compound (Z)-eucomin of (E)-eucomin 
11 (CD3OD)/ 11 (CDCh)/ (CDCh)6,8/ ppm (CDCht,8/ ppm 
ppm ppm 
2 5.34 d, 1.7 5.27 d, 1.8 4.91 s 5.31 d, 1.7 
6 5.96 d, 2.2 5.97 d, 2.2 5.93 d, 2.3 5.90 d, 2.3 
8 5.90 d, 2.2 5.87 d, 2.2 5.99 d, 2.3 6.00 d, 2.3 
9 7.77 bs 7.77 bs 6.87 s 7.80t,1.7 
2'/6' 7.36 d, 8.7 7.24 d, 8.8 7.81 d, 8.8 7.27 d, 8.8 
3'/5' 7.06 d, 8.7 6.94 d, 8.8 6.90 d, 8.8 6.96 d, 8.8 
4'-OCH3 3.89 S 3.84 s 3.85 s 3.87 s 
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Table 4.26: Comparison of 13C NMR data for compound 11 with the literature6 
13C data of J3C data of l3C data of (Z)- l3C data of (E)-
compound 11 compound 11 eucomin eucomin 
(CD30D)/ ppm « CD3)2S0)/ « CD3)2S0)6/ «CD3)2S0)6/ 
ppm ppm ppm 
2 68.4 67.3 74.1 67.1 
3 128.8 127.4 125.5 127.l 
4 186.3 184.0 186.6 184.1 
4a 103.8 102.0 103.2 101.6 
5 165.9 164.7 164.8 164.5 
6 97.4 96.4 96.2 96.2 
7 168.2 167.1 166.7 166.9 
8 96.1 95.0 94.7 94.9 
8a 163.7 162.1 162.5 161.9 
9 137.8 136.4 140.5 136.0 
l' 127.8 126.4 126.6 126.2 
2'/6' 133.2 132.7 133.1 132.4 
3'/5' 115.3 114.6 113.4 114.3 
4' 162.3 160.8 160.6 160.6 
4-0CH3 56.0 55.6 55.2 55.2 
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4.2.12. Structural elucidation of compound 12: 3',S,7-tribydroxy-4'-
metboxyspiro [2H-1-benzopyran-3( 4H), 7'-bicyclo [4.2.0]octa[1,3,S] -trien ]-4-one 
(spectra 12.1-12.12, pp 271-281) 
This compound was isolated as a cream coloured crystalline solid with a melting 
point of 215-217 DC. 
H 
H 
Figure 4.20: Structure of compound 12: 3',5,7-trihydroxy-4'-methoxyspiro[2H-l-benzopyran-
3( 4H), 7' -bicyclo[ 4.2.0) octa[I,3,5)-trien )-4-one 
The mass spectrum [spectrum 12.11] gave a molecular ion [M+] peak at mlz 314. 
This corresponded to a molecular formula of C\7HI40 6. A double bond equivalence of 
eleven was deduced which implied presence of either another double bond or an 
additional ring compared to the usual A, B, C rings and carbonyl group found in the 
previous homoisoflavonoids. UV absorption maxima were obtained at 289 nm (log E 
4.16) and 231 nm (log E 4.15) [spectrum 12.8]. 
The IH NMR spectrum [spectrum 12.1] showed a splitting pattern for the methylene 
protons of 2H-2 and 2H-9 that are typical of scillascillin type compounds. This was 
indicated from the appearance of non-first order resonances at OH 4.51 and OH 4.53 
attributed to 2H-2, the pair of doublets at OH 2.97 (J = 13.4 Hz) and OH 3.49 (J = 13.4 
Hz) attributed to 2H-9 and the absence of the H-3 proton resonance. The fully 
substituted C-3 carbon resonance occurred at oe 55.3 in the l3e NMR spectrum 
[spectrum 12.2]. 
The IH NMR spectrum showed the presence of a methoxy group at OH 3.77. The 
resonances at OH 5.92 (d, J = 2.2 Hz) and OH 5.90 (d, J = 2.2 Hz) indicated a meta-
coupled proton system on the A ring and were assigned to the H-8 and H-6 protons 
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respectively. The UV spectra showed bathochromic shifts with A1Ch (+17 run) and 
NaOAc (+36 run) [spectra 12.9 and 12.10] and this indicated hydroxy groups at the 
C-5 and C-7 positions.14 The presence of a hydroxy group at C-5 was confirmed by 
the downfield resonance of the C-4 carbonyl group at 5c 198.0 in the I3C NMR 
spectrum. Placement of the hydroxy group at the C-7 position was confirmed by the 










mlz 152 I H- shift 






Scheme 4.10: Mass spectral fragmentation pattern for compound 1214 
The pair of doublet resonances at 5H 6.68 and 5H 6.65 (J = < 1 Hz) indicated protons 
para to each other and this implied a 1',3',4',6'- tetrasubstituted B ring. The mass 
spectrum showed a peak at mlz 162 which indicated one methoxy and one hydroxy 
group on the B ring. Since the B ring was tetrasubstituted with two protons para to 
each other, the methoxy group had to be placed at either at the C-3' or C-4' position. 
This was determined by the NOESY spectrum [spectrum 12.7]. A NOESY 
correlation was seen between the H-2 proton and the signal at 5H 6.65. This confirmed 
the signal at 5H 6.65 to be H-5' and implied that the proton para to it was the H-2' 
proton at 5H 6.68. The methoxy group proton resonance at 5H 3.77 showed a NOESY 
correlation with the H-5' proton. This indicated the presence of a methoxy group at 
the C-4' position and the C-3' position was occupied by the hydroxy group. Benzylic 
coupling between the 2H-9 protons and the signal at 5H 6.68 was seen in the COSY 
spectrum [spectrum 12.6] and this confirmed that the resonance belonged to H-2'. 
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The IR spectrum [spectrum 12.12] showed peaks at 3381 cm-I (O-H stretching), 2930 
cm-I (aliphatic C-H stretching), 1644 cm-I (C-O stretching) and 1476 cm-I (aromatic 
C=C stretching). These were consistent with that of the proposed structure. 
Assignment of I3C NMR chemical shifts was done using the HMBC spectrum 
[spectrum 12.5] and comparison with the literature (Table 4.29).15 The NMR data of 
compound 12 was compared to that of 3',5,7-trihydroxy-4'-methoxyspiro[2H-l-
benzopyran-3( 4H), 7'-bicyclo[ 4.2.0]octa[ 1 ,3,5]-trien]-4-one (COMPOUND A) which 
had a methoxy group at the C-4' position and muscomosin (COMPOUND B) which 
had the methoxy group at the C-3' position. From this comparison it was found that 
the IH and I3C NMR data of compound 12 (Table 4.28 and 4.29) agreed more closely 
with that of 3',5,7- trihydroxy-4'-methoxyspiro[2H-l-benzopyran-3(4H),7'-
bicyclo[4.2.0]octa[I,3,5]-triene-4-one, confirming what was expected from NOESY 
correlations. This compound was previously isolated from Muscari armeniacum, 
Muscari botryoides and Drimiopsis maculata.15,16 
H H 
compound A compound B 
Figure 4.21: Structures of compounds A and B 
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Table 4.27: H, 13 C, HMBC, COSY and NOESY data for compound 12 (CD3ODl 
IH/ppm lJC/ HMBC COSY NOESY 
ppm C-+H 
2 a-4.51 d* 74.9 H-9a H-9a 
b-4.53 d* H-5' 
3 55.3 H-9a,b, H-2a,b, 
H-5' 
4 198.0 H-9b, H-2a,b 
4a 102.5 H-8 
5 165.9 H-6 
6 5.90 d, 2.2 97.2 H-8 
7 168.4 
8 5.92 d, 2.2 96.0 H-6 
8a 165.0 H-2a,b, H-8 
9 a-2.97 d, 13.4 35.9 H-2a,b, H-2' H-9b, H-2' H-9b, H-2', 
H-2 
b-3.49 d, 13.4 H-9a, H-2' H-9a, H-2' 
l' 135.5 H-9a,b, H-2a,b, 
H-5', H-2' 
2' 6.68 112.0 H-9a,b H-9a, b 
3' 149.6 H-5', H-2' 
4' 149.6 4'-OCH3, H-5', 
H-2' 
5' 6.65 107.1 4'-OCH3, H-
2b 
6' 135.8 H-9a,b, H-2a,b, 
H-2' 
4'-OCH3 3.77 S 56.8 H-5' 
* The 2H2 proton resonances are superImposed m the IH NMR spectrum (non-first order 
resonances) 
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T bl 428 C d 12 'th th n t IS a e • . ompanson 0 a a or compoun WI e 1 era ure . 
IH NMR data of IH NMR data of IH NMR data of 
compound 12 compound A from compound B from 




2 a-4.51 * 4.51 d,9.0 4.50 s 
h-4.53* 4.53 d, 9.0 
6 5.90 d, 2.2 5.93 d, 2.2 5.91 d, 1.8 
8 5.92 d, 2.2 5.90 d, 2.2 5.89 d, 1.8 
9 a-2.97 d, 13.4 2.97 d, 13.2 2.98 d, 13.2 
h-3.49 d, 13.4 3.49 d, 13.2 3.51 d, 13.2 
2' 6.68 s 6.68 s 6.82 s 
4'-OCH3 3.77 S 3.77 s 
3'-OCH3 3.83 S 
5' 6.65 s 6.65 s 6.51s 
* The 20-2 proton resonances are superimposed in the 10 NMR spectrum (non-first order 
resonances) 
T bl 429 C f l3C NMR d t fi d 12 . h r IS a e . . omparlson 0 a a or compoun WIt iterature . 
IJC data for BC NMR data of l"C NMR data of 





2 74.9 74.9 74.7 
3 55.3 55.3 55.2 
4 198.0 198.4 197.9 
4a 102.5 102.6 102.4 
5 165.9 165.9 165.8 
6 97.2 97.3 97.3 
7 168.4 168.4 168.5 
8 96.0 96.0 96.0 
8a 165.0 165.0 165.0 
9 35.9 36.0 35.9 
l' 135.5 135.7 134.1 
2' 112.0 112.1 109.0 
3' 149.6 149.6 150.8 
4' 149.6 149.6 148.1 
5' 107.1 107.3 110.1 
6' 135.8 135.7 137.2 
4'-OCH3 56.8 56.9 
3'-OCH3 56.7 
109 




2. R1=R3=Rs=OH, Rz=R,rH 
3. R1=R3=OH, Rz=R,rH, Rs=OCH3 
4. R1=OCH3' Rz=R.c=H, RrRs=OH 
S. R1=R,rRs=OH, Rz=H, R3=OCH3 
6. R1=Rr-QH, Rz=H, Rr R.c=OCH3 











8. R1=R3=Rs=OH, Rz=R,rH 
9. R1=R3=OH, Rz=R.c=H, Rs=OCH3 
10. R1=OH, Rz=R,rH, Rr Rs=OCH3 
H 
Figure 4.22: Structures of compounds 2-12 
o 13C NMRd Ii Table 4.3 : ata or compoun d 2 12 *CD OD **CDCI s - 3 , 3 
2* 3 ** 4* 5* 6* 7** 8* 9** 10** 11* 12* 
2 70.1 68.8 69.8 70.5 70.6 68.8 72.3 71.7 71.8 68.4 74.9 
3 48.1 46.8 49.9 48.5 48.2 48.5 73.5 72.2 72.2 128.8 55.3 
4 199.5 197.5 194.0 200.1 200.0 191.9 200.0 198.1 198.3 186.3 198.0 
4a 102.8 102.0 105.2 103.2 103.2 108.6 101.4 100.4 100.5 103.8 102.5 
5 165.8 164.4 164.5 158.2 161.5 153.6 165.8 164.1 164.0 165.9 165.9 
6 97.1 96.5 94.2 93.4 93.8 l35.2 97.4 97.1 95.4 97.4 97.2 
7 168.2 166.0 166.5 158.0 162.7 155.7 168.6 165.8 168.6 168.2 168.4 
8 95.8 95.2 96.7 127.6 130.4 98.9 96.1 95.8 94.5 96.1 96.0 
8a 164.7 163.1 166.7 149.2 155.1 159.8 164.4 163.0 162.7 163.7 165.0 
9 33.0 32.0 33.4 32.9 33.0 32.0 40.7 40.6 40.7 137.8 35.9 
1 ' 130.2 129.8 l30.6 l30.2 129.9 l30.1 126.9 126.0 126.1 127.8 l35.5 
2' 131.1 l30.0 l31.1 l31.2 131.2 l30.2 l32.8 l31.6 l31.5 133.2 112.0 
3' 116.4 114.1 116.3 116.4 116.4 115.5 115.9 1l3.8 113.7 115.3 149.6 
4' 157.2 158.3 157.1 157.2 157.3 154.5 157.5 158.7 158.8 162.3 149.6 
5' 116.4 114.1 116.3 116.4 116.4 115.5 115.9 1l3.8 113.7 115.3 107.1 
6' l31.1 130.0 131.1 131.2 131.2 l30.2 132.8 l31.6 l31.5 133.2 l35.8 
4'- 55.4 55.3 55.2 56.0 56.8 
OCH3 









4.3. Foreward to Experimental 
4.3.1. Nuclear Magnetic Resonance Spectroscopy (NMR Spectroscopy) 
Nuclear magnetic resonance spectroscopy was carried out on either a 400 MHz 
Varian UNITY -!NOVA spectrometer or a 300 MHz Gemini spectrometer. All spectra 
were aquired at ambient temperature in either deuterated chloroform (CDCh), 
deuterated methanol (CD30D), deuterated acetone ((CD3hCO) or deuterated 
dimethylsulfoxide ((CD3hSO). The chemical shifts (5) were recorded in ppm relative 
to the internal standard, tetramethylsilane (TMS), and coupling constants (1) are given 
in Hertz (Hz). 
4.3.2. Infrared Spectroscopy (IR spectroscopy) 
Infrared spectra were recorded using a Nicolet Impact 400D Fourier-Transform Infra-
Red (Ft-IR) spectrometer. Crystalline compounds were analysed using KBr discs and 
non-crystalline samples were dissolved in dichloromethane and analysed on a sodium 
chloride window. Spectra were calibrated against an air background. 
4.3.3. Ultraviolet Absorption Spectroscopy (UV spectroscopy) 
Ultraviolet absorption spectra were obtained on a Varian DMS 300 UV-visible 
spectrometer. The solvent used to record spectra was dichloromethane or methanol 
when bathochromic shift measurements were being obtained. The NaOAc and AICh 
solutions used for bathochromic shifts were prepared by dissolving O.S g of each 
anhydrous salt in 100 mL of methanol. 
4.3.4. Melting Points 
Melting points for crystalline compounds isolated were determined on an Ernst Leitz 
Weltzlar melting point apparatus and are uncorrected. 
4.3.5. Optical Rotations 
Optical rotations were measured at room temperature in either methanol, chloroform 
or acetone using an Optical activity AA-S Polarimeter together with a series A2 
stainless steel (4 X 200 mm) unjacketed flow tube. 
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The optical rotation value was calculated as follows. 
[a]o = 100 ailc 
where a = reading in 0, I = tube length in elm and c = concentration (g/100ml) 
4.3.6. Mass Spectrometry 
The high resolution mass spectrum for compound 1 [spectrum 1.8] was recorded on a 
Kratos 9/50 HRMS instrument. All other mass spectra were recorded on an Agilent 
MS 5973 instrument connected to a GC 6890, except the mass spectrum for 
compound 13 [spectrum 13.9] which was recorded on a Perkin Elmer Turbo Mass 
mass spectrometer connected to a Perkin Elmer Autosystem GC. 
4.1.7. General Chromatography 
The isolation process employed column and thin layer chromatographic techniques. In 
column chromatography, different sized columns were used ranging from 2-8 cm in 
diameter depending on the amount of sample available and purification stage. 
Separation of the crude extracts was generally carried out on a column using Merck 
Art. 9385 silica gel. All separations were carried out under gravity. Both column and 
thin layer chromatographic techniques made use of varying ratios of hexane, 
dichloromethane, ethyl acetate and methanol. Thin layer chromatography was carried 
out on 0.2 mm Si02, aluminium-backed plates (Merck-Art. 5554). The plates were 
developed using anisaldehyde: conc H2S04 : methanol (1 :2:97) spray reagent. The 
plates were first analysed under UV (254 and 366 nm) and then by heating. 
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4.4. Experimental 
Plant material was collected by Dr Neil Crouch of the National Botanical Institute 
from Long Tom Pass. A voucher specimen is retained at the Natal Herbarium (N. 
Crouch 857 NH). 
The bulbs (dry mass 980 g) were chopped into small pIeces, air dried for 
approximately 48 hours and then extracted successively with dichloromethane (mass 
of extract-3.45 g), ethyl acetate (mass of extract-3.81 g) and methanol (mass of 
extract- 2.53 g) by agitation on a Labcon Mechanical Shaker at 140 rpm. Extraction 
with each solvent was carried out for approximately 96 hours. The extracts obtained 
were then filtered and the solvent was removed under reduced pressure at room 
temperature using a BUCHI rotavapor. General chromatographic techniques lead to 
the isolation of twelve compounds: (1) (23S)-17a,23-epoxy-3p,28,29-trihydroxy-27-
norlanost-8-en-24-one, (2) 4'-demethyl-3,9-dihydroeucomin, (3) 3,9-dihydroeucomin, 
(4) 4'-demethyl-5-0-methyl-3,9-dihydroeucomin, (5) 8-0-demethyl-7-0-methyl-3,9-
dihydropunctatin, (6) 7-0-methyl-3,9-dihydropunctatin, (7) 7-hydroxy-3-(4'-
hydroxybenzyl)-5,6-dimethoxy-4-chromanone, (8) 3,5,7 -trihydroxy-3-(4'-
hydroxybenzyl)-4-chromanone, (9) eucomol, (10) 7-0-methyleucomol, (11) (E)-
eucomin and (12) 3',5,7-trihydroxy-4'-methoxyspiro[2H-l-benzopyran-3( 4H), 7'-
bicyclo[ 4.2.0]octa [1 ,3,5]-trien ]-4-one. 
4.4.1. Isolation of compounds 1-12 
The dichloromethane extract was eluted with a dichloromethane: ethyl acetate: 
methanol step gradient [100% dichloromethane (fractions 1-160), 10% ethyl acetate 
in dichloromethane (fractions 161-199), 15% ethyl acetate in dichloromethane 
(fractions 200-322), 20% ethyl acetate in dichloromethane (fractions 323-343), 40% 
ethyl acetate in dichloromethane (fractions 344-387), 60% ethyl acetate in 
dichloromethane (fractions 388-404), 80% ethyl acetate in dichloromethane (fractions 
405-439), 100% ethyl acetate (fractions 440-470), 10% methanol in ethyl acetate 
(fractions 471-491) and 20% methanol in ethyl acetate (fractions 492-512). Fractions 
30-42 yielded compound 10 that was further purified by chromatography with 100% 
dichloromethane as eluent. Compound 3 was isolated in fractions 93-100 that was 
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further purified by chromatography with 20% ethyl acetate in hexane as eluent. 
Fractions 177-180 yielded compound 9 and fractions 211-223 yielded compound 7. 
Compound 1 was isolated in fractions 405-427 and was further purified by 
chromatography using 60% ethyl acetate in hexane as eluent. All purification steps 
were carried out using Pasteur pipette columns. 
The ethyl acetate extract was eluted with a dichloromethane: ethyl acetate: methanol 
step gradient [100% dichloromethane (fractions 1-30), 10% ethyl acetate in 
dichloromethane (fractions 31-60), 20% ethyl acetate in dichloromethane (fractions 
61-90),40% ethyl acetate in dichloromethane (fractions 91-120), 60% ethyl acetate in 
dichloromethane (fractions 121-147),80% ethyl acetate in dichloromethane (fractions 
148-161), 100% ethyl acetate (fractions 162-184), 5% methanol in ethyl acetate 
(fractions 185-215). Fractions 1-30 yielded crystalline material that on purification by 
chromatography with 10% methanol in ethyl acetate as eluent yielded compounds 4 
and 11. Compound 11 was purified further with 100% dichloromethane. Compound 5 
was isolated from fractions 47-51 and was further purified by chromatography with 
100% dichloromethane as eluent. Fractions 64-67 yielded compound 12, which was 
further purified by chromatography with 100% dichloromethane as eluent. Fractions 
76-80 yielded compound 6 that was further purified by chromatography with 10% 
ethyl acetate in dichloromethane and then finally 100% ethyl acetate. 
The methanol extract was eluted with a dichloromethane: ethyl acetate step gradient 
[100% dichloromethane (fractions 1-10), 20% ethyl acetate in dichloromethane 
(fractions 11-15) and 40% ethyl acetate in dichloromethane (fractions 16-25). 
Fraction 11 yielded compound 8, which was further purified by chromatography with 
100% dichloromethane as the eluent. Fractions 18-19 yielded compound 2. 
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4.5. PHYSICAL DATA 
4.5.1. Physical data for compound 1 
Name: (23S)-17a, 23-epoxy-3 p,28,29-trihydroxy-27 -norlanost-8-en-24-one 
Yield: 7.0 mg 
Physical description: Orange gum 
Optical rotation: not determined because sample decomposed 
Mass spectrum*: [M+] at mlz 474.33398, C29~60S requires 474.33453 g.mor l 
HRMS: mlz (reI. int) 474.33398 (51),459.30952 (27), 456.32257 (8), 
417.29715 (25), 345.24182 (39), 305.21341 (30),271.20423 
(35), 167.10605 (50), 121.10149 (58),83.08548 (62), 
57.03385 (tOO) 
Infrared data: v:!' cm-I: 3421,2934,1737,1461 
JH NMR data**: CDCh (Table 4.1) 
l3e NMR data**: CDCh (Tables 4.1 and 4.2) 
4.5.2. Physical data for compound 2 
Name: 4'-demethyl-3,9-dihydroeucomin 
Yield: 6.3 mg 
Physical description: Yellow crystals 
Melting point: 96-99·C (lit: t03-t04·ci 
Optical rotation: [a]D -30· MeOH, c=0.05 (lit: [a]D -34· MeOH)3 
Mass spectrum: [~] at mlz 286, CI6HI40S requires 286 g.mor l 
ElMS: mlz (reI. int) 286 (30), 179 (65), 153 (42), 152 (11), t07 (tOO) 
Infrared data: v:!' cm-I: 3374,2920,2852,1641, 1520, 1457 
UV data: A;:Cb (log E): 324 (4.00), 267 (4.46), 238 (4.76) 
Bathochromic shift: AICh (20 nm), NaOAc (36 nm) 
JH NMR data: CD30D (Tables 4.3 and 4.4) 
J3e NMR data: CD30D (Tables 4.3 and 4.5) 
* Sample had decomposed prior to running of mass spectrum therefore spectrum from N. 
Moodley's thesis2 was used. 
** Own NMR spectra was not well resolved (see original IH NMR spectrum [spectrum 1]) 
therefore spectra from N. Moodley's earlier work on Ledebouria zebrina2 which had been shown 
on computer were used. 
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4.5.3. Physical data for compound 3 
Name: 3,9-dihydroeucomin 
Yield: 5.8 mg 
Physical description: White crystals 
Melting point: 152-154°C (lit 161-163 0C)8 
Optical rotation: sample size too small to carry out optical rotation (lit: [a]D +38 ° , 
CHCh)8 
Mass spectrum: [M+] at mlz 300, C17HI60S requires 300 g.mor l 
ElMS: mlz (reI. int) 300 (11),179 (1.9), 153 (2.5), 121(100) 
Infrared data: V::;I cm-I: 3364,2929,1644,1515,1478 
UV data: A;:cll nm (log e): 293 (4.24) 
Bathochromic shift: AlCh (32 nm), NaOAc, (32 nm) 
IH NMR data: CDCh (Tables 4.6 and 4.7) 
13e NMR data: CDCh (Table 4.6) 
4.5.4. Physical data for compound 4 
Name: 4'-demethyl-5-0-methyl-3,9-dihydroeucomin 
Yield: 6 mg 
Physical description: Colourless crystals 
Melting point: 201-203°C (lit 196-197 °cl 
Optical rotation: sample size too small to carry out optical rotation (lit: [a]D _38°, 
dioxane)9 
Mass spectrum: [M+] at mlz 300, C17H I60 S requires 300 g.mor
l 
ElMS: mlz (reI. int) 300 (78), 193 (48), 167 (100), 166 (60), 107 (54) 
Infrared data: V:;I cm-I: 3419,2925,2853, 1736, 1590 
UV data: A;,:cll nm (log e): 283 (2.83),232 (3.77) 
Bathochromic shifts: AICh (0 nm), NaOAc (20 nm) 
IH NMR data: CD30D (Tables 4.8 and 4.9), (CD3)2CO (Table 4.9) 
13e NMR data: CD30D (Table 4.8) 
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4.5.5. Physical data for compound 5 
Name: 8-0-demethyl-7-0-methyl-3,9-dihydropunctatin 
Yield: 8.1 mg 
Physical description: Yellow crystals 
Melting point: 178-180°C (lit 172-174oC)7 
Optical rotation: [a]n -1 T MeOH, c=0.06 (no literature value available) 
Mass spectrum: [M+] at mlz 316, C17H1606 requires 316 g.mor l 
ElMS: mlz (reI. int) 316 (53), 209 (58), 183 (11), 107 (100) 
Infrared data: V:;I cm-I: 3414, 2920, 2857,1652, 1514, 1383 
UV data: A;:CI2 nm (log 8): 368 (3.13), 295 (3.53), 235 (4.60) 
Bathochromic shifts: AICh (14 nm), NaOAc (0 nm) 
IH NMR data: CDCh (Table 4.11), CD30D, (Tables 4.10 and 4.11) 
13e NMR data: CD30D (Tables 4.10 and 4.12) 
4.5.6. Physical data for compound 6 
Name: 7 -O-methyl-3,9-dihydropunctatin 
Yield: 5.5 mg 
Physical description: Yellow amorphous solid 
Optical rotation: sample size too small to carry out optical rotation (no literature 
value available) 
Mass spectrum: [M+] at mlz 330, CIsHIS06 requires 330 g.mor l 
ElMS: mlz (reI. int) 330 (50), 223 (12), 197 (5), 107 (100) 
Infrared data: V~:;I cm-I: 3414,2932, 2852, 1641, 1520, 1463 
UV data: A;:CI2 nm (log 8): 287 (3.18), 229 (3.21) 
Bathochromic shifts: AICh (25 nm), NaOAc (0 nm) 
IH NMR data: CD30D (Tables 4.13 and 4.14), CDCh (Table 4.14) 
13e NMR data: CD30D (Tables 4.13 and 4.15) 
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4.5.7. Physical data for compound 7 
Name: 7 -hydroxy-3-(4' -hydroxybenzyl)- 5,6-dimethoxy-4-chromanone 
Yield: 8.0 mg 
Physical description: Yellow amorphous solid 
Optical rotation: [a]o -30· MeOH, c=0.05 
Mass spectrum: [M+] at mlz 330, C i sHIs06 requires 330 g.mor
l 
ElMS: mlz (reI. int) 330 (71), 223 (28), 197 (32), 196 (38), 107 (100) 
Infrared data: V~:;:l cm· l : 3368,2921,2855, 1618, 1525, 1486 
UV data: A;~C12 nm (log e): 321 (3 .53), 277 (3.87), 232, (4.56) 
Bathochromic shifts: AICh (0 nm), NaOAc (43 nm) 
IH NMR data: CDCh (Table 4.16) 
13e NMR data: CDCh (Tables 4.16 and 4.17), CD30D (Table 4.17) 
4.5.8. Physical data for compound 8 
Name: 3,5,7 -trihydroxy-3-( 4'-hydroxybenzyl)-4-chromanone 
Yield: 7.7 mg 
Physical description: Yellow crystals 
Melting point: 99-10 I·C (lit 105-107 .C)6 
Optical rotation: [a]o +71· acetone, c=0.07 (lit: [a]o-90· acetone)6 
Mass spectrum: [M+] at mlz 302, CI6HI406 requires 302 g.mor l 
ElMS: mlz (reI. int) 302 (11), 195 (50), 153 (62), 107 (100) 
Infrared data: V~:;:l cm· l : 3337,2915,2845, 1646, 1521 
UV data: A;!2C12 nm (log e): 291 (3 .69) 
Bathochromic shifts: A1Ch (16 nm), NaOAc (37 nm) 
IH NMR data: CD30D (Table 4.18 and 4.19), (CD3)2CO (Table 4.19) 
13e NMR data: CD30D (Table 4.18) 
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4.5.9. Physical data for compound 9 
Name: eucomol 
Yield: 15.6 mg 
Physical description: Yellow crystals 
Melting point: 128-130°C (lit 133-134 0C)6 
Optical rotation: [a]o -31 ° CHCh, c=0.08 (lit: [a]o _32°/_26° CHCh)6 
Mass spectrum: [~] at mlz 316, C17H1606 requires 316 g.mor l 
ElMS: mlz (reI. int) 316 (1.5), 195 (2.4), 153 (4.1), 121 (100) 
Infrared data: V:;I cm-I : 3408,2922,2848, 1638, 1513 
UV data: A;:CI2 run (log e): 293 (4.15), 235 (4.59) 
Bathochromic shifts: AICh (15 run), NaOAc (34 run) 
IH NMR data: CDCh (Tables 4.20 and 4.21) 
13e NMR data: CDCh (Table 4.20) 
4.5.10. Physical data for compound 10 
Name: 7-0-methyleucomol 
Yield: 2 mg 
Physical description: Cream crystals 
Melting point: 78-81 °C (lit 83-84 0C)6 
Optical rotation: sample size too small to carry out optical rotation (lit: [a]o -27" 
CHCh)6 
Mass spectrum: [~ at mlz 330, CisHIS06 requires 330 g.mor l 
ElMS: mlz (reI. int) 330 (2), 209 (15), 167 (7), 121 (100) 
Infrared data: V:;I cm-I: 3381,2921,2848, 1651, 1512 
UV data: A;:C12 run (log e): 293 (3.42), 232 (3.50) 
Bathochromic shifts: AICh (18 run), NaOAc (0 run) 
IH NMR data*: CDCh (Tables 4.22 and 4.23) 
13e NMR data*: CDCh (Table 4.22) 
* Sample was weak (see original IH NMR spectrum [spectrum 10)) and NMR spectra weren't 
weD resolved therefore spectra from T. Pohl's earlier work on Ornithogalum longibracteatuml3 
which had been shown on computer were used. 
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4.5.11. Physical data for compound 11 
Name: (E)-eucomin 
Yield: 9.8 mg 
Physical description: Yellow crystals 
Melting point: 206-208 (lit 199-201 oC)6 
Optical rotation: sample was contaminated (lit: [a]o 0°)6 
Mass spectrum: [Ml at mlz 298 requires 298 g.mor l 
ElMS: mlz (reI. int) 298 (100), 153 (75), 146 (48) 
Infrared data: v:;' cm-I: 3374,2961,2926,2857,1646, 1515 
UV data: A;:CI2 nm (log e): 357 (3.44), 232 (4.27) 
Bathochromic shifts: AICl) (39 nm), NaOAc (20 nm) 
IH NMR data: CDCl) (Table 4.25), CD30D (Tables 4.24, 4.25) 
l3e NMR data: (CD3)2S0 (Table 4.26), CD30D (Tables 4.24, 4.26) 
4.5.12. Physical data for compound 12 
Name: 3',5,7-trihydroxy-4'-methoxyspiro[2H-1-benzopyran-3(4H),7'-
bicyc10[4.2.0]octa[I,3,5]-trien]-4-one 
Yield: 5.9 mg 
Physical description: cream crystals 
Melting point: 215-21 TC (lit 209-211 0C)15 
Optical rotation: sample size too small to carry out optical rotation (lit: [a]o + 11° 
MeOH)15 
Mass spectrum: [M+] at mlz 314 requires 314 g.mor l 
ElMS: mlz (rel.int) 314 (44), 162 (16), 153 (100), 152 (42) 
Infrared data: v:;'cm-I: 3381, 2930, 2849,1644,1476 
UV data: A;:CI2 nm (log e): 231 (4.15),289 (4.16) 
Bathochromic shifts: AICl) (17 nm), NaOAc (36 nm) 
IH NMR data: CD30D (Tables 4.27 and 4.28) 
l3e NMR data: CD30D (Tables 4.27 and 4.29) 
120 
4.6 References 
1. Parrilli, M., Lanzetta, R, Adinolfi, M., Mangoni, L., 1980. Glycosides from 
Muscari comosum-III. The structure of further authentic aglycones. 
Tetrahedron. 36, 3591-3596. 
2. Moodley, N., 2001. The Chemical Investigation of Ledebouria zebrina and 
Scilla natalensis. MSc Dissertation. University of Natal. South Africa. pp 62-
65. 
3. Adinolfi, M., Barone, G., Lanzetta, R., Laonigro, G., Mangoni, L., Parrilli, M., 
1985. Three 3-benzyl-4-chromanones from Muscari comosum. 
Phytochemistry. 24,624-626. 
4. Adinolfi, M., Lanzetta, R, Laonigro, G. and Parrilli, M., 1986. lH and 13C 
chemical shift assignments of homoisoflavanones. Magnetic Resonance In 
Chemistry. 24,663-666. 
5. Pohl, T., 1999. The Chemical Investigation of Ledebouria ovatifolia, Clivia 
caulescens and Haemanthus pauculifolius. MSc Dissertation. University of 
Natal. South Africa. pp 24-29. 
6. Heller, W. and Tamm, c., 1981. Homoisoflavanones and biogenetically 
Related Compounds. Fortschritte der Chemie Organischer Naturstoffe. 40, 
106-152. 
7. Adinolfi, M., Barone, G., Belardini, M., Lanzetta, R, Laonigro, G., Parrilli, 
M., 1984. 3-Benzyl-4-chromanones from Muscari comosum. Phytochemistry. 
23,2091-2093. 
8. Heller, W., Andermatt, P., Schaad, W.A. and Tamm, C., 1976. 
Homoisoflavanone. IV. Neue inhaltsstoffe der eucomin-reihevon Eucomis 
bicolor. Helvetica Chimica Acta. 59, 2048-2058. 
9. Finckh, R.E. and Tamm, c., 1970. The homoisoflavones III. Isolation and 
structure of punctatin, 3,9-dihydropunctatin, 4'-O-methyl-3,9-dihydro-
punctatin, 4' -demethyleucomin and 4' -demethyl-5-0-methyl-3 ,9-dihydro-
eucomin. Experientia. 26,472-473. 
10. Koorbanally, C., 2000. Extractives from the Hyacinthaceae. MSc Dissertation. 
University of Nata!. South Africa. pp 37-42. 
11. Kemp, W., 1991. Organic Spectroscopy. The MacMillan Press Ltd. pp 158-
164. 
121 
12. Crouch, N.R, Bangani, V., Mulholland, D.A., 1999. Homoisoflavanones from 
three South African Scilla species. Phytochemistry. 51. 943-946. 
13. Pohl, T., 2002. Extractives from the Amaryllidaceae and the Hyacinthaceae. 
Ph.D. Thesis. University of Natal. South Africa. pp 154-157. 
14. Adinolfi, M., Barone, G., Belardini, M., Lanzetta, R, Laonigro, G., Parrilli, 
M., 1985. Homoisoflavonones from Muscari comosum bulbs. Phytochemistry. 
24, 2423-2426. 
15. Adinolfi, M., Corsaro, M., Lanzetta, R., Laonigro, G., Mangoni, L., Parrilli, 
M., 1987. Ten homoisoflavanones from two Muscari species. Phytochemistry. 
26, 285-290. 
16. Koorbanally, C., Crouch, N.R, Mulholland., D.A., 2001. Scillascillin-type 
homoisoflavanones from Drimiopsis maculata (Hyacinthaceae). Biochemical 
Systematics and Ecology. 29, 539-541. 
122 
CHAPTER 5: EXTRACTIVES FROM AGAPANTHUS 
INAPERTUS 
5.1. Introduction 
Investigation of the acidic chloroform extract of Agapanthus inapertus has led to the 
isolation of a lignan precursor (13) dihydroconiferyl alcohol (3-(4'-hydroxy-3'-
methoxyphenyl)-l-propanol) and a lignan (14) isolariciresinol. The IH NMR 
spectrum of the crude basic chloroform extract did not show any characteristic peaks 












Figure 5.1: Compounds isolated from Agapanthus inaperlus 
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5.2. Results and Discussion 
5.2.1. Structural elucidation of compound 13: dihydroconiferyl alcohol (spectra 
13.1-13.10, pp 282-291) 
This compound was isolated as a yellow amorphous solid. 
OH 
Figure 5.2: Structure of compound 13: dihydroconiferyl alcohol 
The mass spectrum [spectrum 13.9] of compound 13 gave a molecular ion [~] peak 
of mlz 182, which corresponded to a molecular formula of C IOHI40 3• Fragmentation 
between C-2 and C-3 resulted in the loss of 45 mass units and gave a peak at mlz 137. 
This corresponded to a hydroxymethoxytropylium ion. 
The infrared spectrum [spectrum 13.10] showed a peak at 3379 cm-1 that indicated 
the presence of hydroxy substituents. The strong peaks at 2932 and 2852 cm-1 
corresponded to the C-H stretching of methine and methylene groups. The peaks at 
1601 and 1515 cm-1 corresponded to the C=C stretching of the aromatic ring. The 
peaks at 1279 and 1033 cm-1 are characteristic ofC-O stretching. 
The resonances at OH 3.66 (2H, t, J= 6.4 Hz), OH 1.85 (2H, m) and OH 2.62 (2H, 1, J= 
7.5 Hz) in the IH NMR spectrum [spectrum 13.1] indicated the presence of three 
methylene groups. The resonance at OH 3.66 was deshielded because it was attached to 
an oxygen atom. Its corresponding carbon resonance occurred at oe 62.3 in the \3C 
NMR spectrum [spectrum 13.2] and was assigned to the C-1 position because this 
resonance showed HMBC correlations [spectrum 13.5] to 2H-2 (OR 1.85) and 2H-3 
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(OH 2.62). The 2H-2 and 2H-3 resonances were assigned through the HMBC 
spectrum. Their corresponding carbon resonances occurred at Oc 34.5 and Oc 31.7 
respectively. 
The strong singlet peak at OH 3.85 integrating to three protons in the IH NMR 
spectrum was characteristic of protons of a methoxy group. The doublet resonance at 
OH 6.66 (J = 2.0 Hz) indicated a meta-coupled proton which was assigned to H-2' 
because its corresponding carbon resonance at Oc 120.9 showed HMBC correlations 
to 2H-3 and the double doublet resonance at OH 6.67 (J = 7.8, 2.0 Hz). The double 
doublet resonance at OH 6.67 (J = 7.8, 2.0 Hz) indicated ortho-coupling as well as 
meta-coupling and was therefore assigned to the protons at the C-6' position. The 
doublet resonance at OH 6.81 (J = 7.8 Hz) was attributed to the H-5' proton. 
The C-l' position had to be substituted because there was meta-coupling between the 
H-2' and H-6' protons. The other positions that were substituted were the C-3' and C-
4' positions. The methoxy group proton resonance showed a NOESY correlation 
[spectrum 13.7] to the H-2' proton resonance and was therefore placed at the C-3' 
position. NOESY correlations between 2H-3 and H-2' and H-6' allowed placement of 
the propanol group at the C- l' position. The remaining hydroxy group was then 
placed at the C-4' position. NOESY correlations confirmed the structure. 
OH 
Figure 5.3: Diagram showing NOESY correlations for compound 13 
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Figure 5.4: Diagram showing COSY coupling for compound 13 
Compound 13 was found to be the known compound dihydroconiferyl alcohol (or 
3-(4' -hydroxy-3' -methoxyphenyl)-l-propanol), which is a typicallignan precursor. 1 
Table 5.1: H, 13 C, HMBC, NOESY and COSY data for compound 13 (CDCh) 
IHlppm -rrCI HMBC NOESY COSY 
ppm 
l' 133.7 2H-2, 2H-3, H-5' 
2' 6.66 d, 2.0 120.9 2H-3, H-6' 3'-OCH3, H-6' 
2H-2, 2H-3, 
2H-l 
3' 146.4 3'-OCH3, H-2', H-
5' 
4' 143.7 H-5', H-2', H-6' 
5' 6.81 d,7.8 114.2 H-6' H-6' 
6' 6.67 dd, 2.0, 111.0 2H-3, H-2' 2H-2, 2H-3, H-2', H-5' 
7.8 H-5',2H-l 
1 3.66 t, 6.4 62.3 2H-2,2H-3 2H-2, 2H-3, 2H-2 
H-2', H-6' 
2 1.85 m 34.5 2H-3,2H-l 2H-3, 2H-l 2H-3,2H-l 
H-2', H-6' 
3 2.62 t, 7.5 31.7 2H-2, 2H-l, H-2', 2H-2, 2H-l, 2H-2 
H-6' H-2', H-6' 
3'-OCH3 3.85 s 55.8 H-2' 
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5.2.2. Structural elucidation of compound 14: isolariciresinol (spectra 14.1-14.10, 
pp 292-301) 
Compound 14 was isolated as a white crystalline solid with a melting point of 148-
150·C. 
OH 
Figure 5.5: Structure of compound 14: isolariciresinol 
The mass spectrum [spectrum 14.9] of compound 14 showed a molecular ion [Ml 
peak at mlz 360. This corresponded to a molecular formula of C2oH2406. The peaks at 
mlz 342 (~ -18) and mlz 311 (~ -18-31) were due to the loss of water and loss of 
water and a CH20H fragment respectively, which is typical of a primary alcohol. 
The IR spectrum [spectrum 14.10] showed peaks at 3374 cm-1 due to O-H stretching, 
2927 cm-1 due to C-H stretching and 1603 cm-1 due to aromatic C=C stretching. The 
peak at 1031 cm-1 was due to C-O stretching. 
The BC NMR spectrum [spectrum 14.2] indicated the presence of twenty carbon 
signals: two methoxy group resonances, twelve aromatic (five methine and seven 
quaternary) resonances and six aliphatic (three methylene and three methine) 
resonances. 
The IH NMR spectrum [spectrum 14.1] indicated the presence of two aromatic ring 
systems. A third ring had to be present to account for the nine double bond 
equivalents indicated from the molecular formula. One aromatic ring was found to be 
1,3,4-trisubstituted. The doublet resonances at OH 6.57 (J = 1.8 Hz) and OH 6.82 (J = 
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8.0 Hz) were attributed to H-2 and H-5 respectively and the double doublet resonance 
at OH 6.62 (J = 8.0, 1.8 Hz) was attributed to H-6. The methoxy group indicated by the 
singlet resonance integrating to three protons at OH 3.80 was placed at the C-3 position 
because a NOESY correlation was seen between this resonance and H-2 in the 
NOESY spectrum [spectrum 14.7]. The resonance at oe 146.7 was assigned to C-3 
because the HMBC spectrum [spectrum 14.5] showed correlations between this 
resonance and with the methoxy group at OH 3.80 and H-5. 
The second aromatic ring was found to be 1 ',3',4',6'-tetrasubstituted. The methoxy 
group resonance at OH 3.83 was placed at C-3' because this resonance showed a 
NOESY correlation to H-2'. The singlet at OH 6.55 was assigned to H-2' because it 
showed a correlation with 2H-7' in the NOESY spectrum. HMBC correlations were 
also seen between C-3' and C-4' and the H-2' resonance. The other singlet resonance 
at OH 6.27 was assigned to H-5' because NOESY correlations were seen between this 
resonance and those of H-7 and H-5. HMBC correlations were also seen between C-
3', C-I', C-4', C-7 and the H-5' resonance. 
HMBC correlations was observed between C-l, C-2, C-6, C-9 and C-6' and the 
doublet resonance at OH 3.70 attributed to H-7. Coupling was seen between the 
multiplet resonance at OH 1.84, attributed to H-8, with H-8', H-7, and H-9a, and 
between the mUltiplet resonance at OH 1.99, attributed to H-8', with H-8, H-7' and 2H-
9' in the COSY spectrum [spectrum 14.6]. This confirmed arrangement of the two 
phenylpropanoid groups (see Section 3.1). 
The relative stereochemistry of the molecule was determined using the NOESY 
spectrum. A NOESY correlation was seen between H-7 and H-8' that confirmed the 
cis-stereochemistry of these protons. The ~-stereochemistry of H-8 was based on the 
NOESY interaction between H-8 and H-2. 
A literature search of compound 14 showed that the I3C NMR data matched that of 
the known compound (+)-isolariciresinol (Table 5.3), previously isolated from 
Araucaria angustijolia.2 However, the optical rotation for compound 14 could not be 
obtained because the sample had decomposed. 
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Table 5.2: IH, 13C, HMBC, NOESY and COSY data for compound 14 CDCh) 
IHlppm 13CI HMBC NOESY COSY 
ppm 
1 132.8 H-7, H-2, H-6 
2 6.57 d, 1.8 111.4 H-7 H-8, H-7, 3-
OCH3 
3 146.7 3-0CH3, H-5 
4 143.5 
5 6.82 d, 8.0 114.2 H-5', H-6 H-6 
6 6.62 dd, 8.0, 1.8 122.4 H-2, H-7 H-7, H-8, H-5 
H-5 
7 3.70 d* 47.9 H-9b, H-5', H- H-2, H-6, H-8, H-
2 H-5', H-8, 9a 
H-8', H-9b' 
8 1.84 m 48.0 H-9b H-2, H-6, H-9a, H-
H-7 7,H-8' 
9 a-3.50 dd, 11.3,5.5 63.0 H-7 H-9b H-8, H-
9b, H-7 
b-3.76dd,I1.1,2.9 H-9a H-9a 
l' 127.5 H-7', H-5' 
2' 6.558 110.1 3'-OCH3, H-
7' 
3' 144.8 3'-OCH3, H-
5',H-2' 
4' 144.2 H-5', H-2' 
5' 6.278 115.5 H-5, H-7 
6' 136.9 H-7 
7' 2.75 dd, 11.4,5.1 33.3 H-2' H-2', H-8' H-8' 
8' 1.99m 40.1 H-9a,b, H-9b', H-7', H-7', H-
H-7, H-9a' 8, H-9a' 
9' a-3.70 dd* 66.4 H-9b', H-8' H-8', H-
9b' 
b-3.86 dd, 11.0,3.6 H-9a', H-7, H-9a' 
H-8' 
3'-OCH3 3.838 55.9 H-2' 
3-0CH3 3.808 56.0 H-2 
* Peaks superImposed therefore coupling constants could not be determined 
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Table 5.3: Comparison of l3C NMR data for compound 14 with (+)-
isolariciresinol2 
I3C (CDCI)! ppm I3C lit (CDCI)z! ppm 
1 132.8 132.6 
2 111.4 112.0 
3 146.7 145.2* 
4 143.5 143.5 
5 114.2 114.5 
6 122.4 121.9 
7 47.9 47.4 
8 48.0 47.5 
9 63.0 62.1 
l' 127.5 127.2 
2' 110.1 110.6 
3' 144.8 147.1 * 
4' 144.2 144.1 
5' 115.5 115.8 
6' 136.9 136.8 
7' 33.3 32.8 
8' 40.1 39.5 
9' 66.4 65.7 
3'- 55.9 55.6 
OCH3 
3-0CH3 56.0 55.6 
* .1 
. Values appear lOcorrect 10 the literature, corrected WIth HMBC experIment 
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5.3. Experimental 
The roots of Agapanthus inapertus were collected from God's Window, Mpumalanga 
and a voucher specimen is retained at the National Botanical Institute, Durban (N. 
Crouch 946 NH). The dried roots (dry mass- 850g) were extracted on a Labcon shaker 
at room temperature for forty-eight hours with 95% ethanol and the solvent was 
removed under reduced pressure to yield 3.51 g of extract. Th extract was dissolved in 
100 mL of water, acidified to pH 5 and extracted five times with 200 mL portions of 
chloroform. The acidic chloroform extracts were combined and the solvent removed 
under reduced pressure to yield 1.03 g of acidic chloroform extract. The aqueous 
portion was then basified to pH 10 and extracted five times with 200 mL portions of 
chloroform as above. The solvent was removed under reduced pressure to yield 0.67 g 
of basic chloroform extract. Only the acidic chloroform extract was worked on. The 
lH NMR spectrum of the crude basic chloroform extract did not show interesting 
results and was not worked on. 
5.3.1. Isolation of compounds 13 and 14 
The acidic chloroform extract was chromatographed over silica gel using a column 
and eluted with a dichloromethane: ethyl acetate step gradient starting with 100% 
dichloromethane (fractions 1-16), then 25% (fractions 17-22), 50% (fractions 23-32), 
75% (fractions 33-36) ethyl acetate in dichloromethane and finally 100% (fractions 
37-42) ethyl acetate. 100 mL fractions were collected. Fraction 5 yielded compound 
13, which was further purified by repeated column chromatography using 5% ethyl 
acetate in dichloromethane. Fractions 18-21 yielded compound 14. This was further 
purified by repeated column chromatography using 20% ethyl acetate in 
dichloromethane. 
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5.4. Physical data 
5.4.1 Physical data for compound 13 
Name: dihydroconiferyl alcohol 
Yield: 3.7 mg 
Physical description: Yellow amorphous solid 
Optical rotation: sample size too small to carry out optical rotation 
Mass spectrum: [M+] at mlz 182, CIOHI40 3 requires 182 g.mor
l 
ElMS: mlz (reI. int) 182 (77), 138 (75), 137 (100), 123 (25), 122 (35) 
Infrared data: V:;l em-I: 3379,2932,2852,1601,1515, 1279,1033 
UV data: A.;:C12 (log E): 281 (3.58),233 (3.76) 
IH NMR data: CDCh (Table 5.1) 
13e NMR data: CDCh (Table 5.1) 
5.4.2. Physical data for compound 14 
Name: isolariciresinol 
Yield: 8.0 mg 
Physical description: White crystals 
Melting point: 148-150°C (lit 155-157 0C)I 
Optical rotation: sample decomposed (lit: [a]D+ 68° acetone)1 
Mass spectrum: [M+] at mlz 360, C2oH2406 requires 360 g.mor l 
ElMS: mlz (reI. int) 360 (88), 342 (24), 311 (1 00) 
Infrared data: V:;l em-I: 3374, 2927, 2853, 1603, 1512, 1467, 1286, 1031 
UV data: A.;:C12 (log E): 283 (3.58),231 (3.88) 
IH NMR data: CDCh (Table 5.2) 
13e NMR data: CDCh (Table 5.2 and 5.3) 
132 
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Recently the taxonomy of the Hyacinthaceae has been under review. The findings of 
this work are interesting in that the types of compounds isolated from Eucomis 
montana are similar to those previously isolated from the Hyacinthoideae subfamily 
of the Hyacinthaceae. Given the well documented occurrence of homoisoflavonoids 
in this family, it is not surprising that this is the major class of compound isolated in 
this work. Six 3-benzyl-4-chromanone, three 3-benzyl-3-hydroxy-4-chromanone, one 
3-benzylidenyl-4-chromanone and one scillascillin type homoisoflavonoids were 
isolated. The 5,7-dioxy substitution pattern is a notable feature of all of the 
homoisoflavonoids isolated from species of the genus Eucomis. Of the eleven 
homoisoflavonoids belonging to the four different classes that have been found here 
all were para-disubstituted, except the scillascillin type. A novel homoisoflavonoid, 
7 -hydroxy-3-( 4'-hydroxybenzyl)-5,6-dimethoxy-4-chromanone was isolated. A 
eucosterol type nortriterpenoid, which is a less common type of compound isolated 
from the family, was also isolated. 
In this chemical investigation of Agapanthus inapertus a lignan precursor and a lignan 
were found. Dihydroconiferyl alcohol is a common lignan precursor. It is the first 
time that a lignan (isolariciresinol) has been reported from the Agapanthus family. 
The structures of the compounds isolated are shown in Figure 6.1. 
Future work will involve collaboration with other universities to screen compounds 
isolated for anti-inflammatory, antiviral, antibacterial and antifungal properties. The 
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Spectrum 9.11: Mass spectrum of compound 9 
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Spectrum 10.7: NOESY spectrum of compound 10 (CDCb) 
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Spectrum 10.9: UV spectrum of compound 10 with AlCh 
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Spectrum 10.10: UV spectrum of compound 10 with NaOAc 
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Spectrum 12.5: HMBC spectrum of compound 12 (CD30D) 
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Spectrum 12.8: UV spectrum of compound 12 
278 
I , 
?UIJ/~- . . '-. , / , , . / ' ~ . 
! / -\ 
1~61 / \\. 
! I ·. /7, 
...., ORIGINAL ~ / \. . \\ 
~, . '/ J , 
~ 1.01 // \ \ 
I ' I ~ \ , /' / \ \ , 
J , " O - ./,,, " .OJ ././ " ........ , . / ../ '- ----. 
I ~---- ---- .~-~ 
a~ct::= I " r -;---
"A-ft · 
ACoDU. 2g0 300 320 
\,AJavelGiigth (uml 
.340 
Spectrum 12.9: UV spectrum of compound 12 with AICh 
I ORIGINAL 
I . /~"""\. " I / " 
I :. / \ " \ , I \ 
1.V.1," I \ 
I \ , / \ , . . / \ , . '. \ 
'I \ I ' \ ./"~, 
I I \ ./" "-0.61 / ..v- ' " 
" 
/ . ~ . \., " , 
/ / . , " 
./ J '- " I /., _____ .. 1,/ ___ ____ 
~---- ----'"" n - I . . IJ~ --- ~-'I~··------·--.---------r-------~Ir~. ------~r_---
"'°0 ' ~u "nn "'vv 
lili"n',...i,... ..... ·h- ;'''m' \ •• a.v.~ .. " .. I ,II" I 
."AO "' .... 
Spectrum 12.10: UV spectrum 'of compound 12 with NaOAc 
279 
H 




































o B _1 T'- '-r.--r-.,--r-r-.-' . , 
3GOO 3400 3200 3000 2800 2600 2400 2200 2000 1 BOO 1600 1400 1200 1000 
Wavenumbers (cm-1) 
50ectrum 12.12: IR spectrum of compound 12 
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Spectrum 13.5: lIMBC spectrum of compound 13 (CDCh) 
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